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1. Abstract 
Regulatory T (Treg) cells are essential for immune homeostasis, maintaining peripheral 
tolerance and preventing autoimmune diseases. Moreover, cancer cells and pathogens 
may take advantage of the suppressive capacity to escape from the immune response. 
Thus, the regulation of Treg cells represents an essential mechanism to build an 
adequate response against threats and to keep immunological self-tolerance. This thesis 
showed that the Treg cells manifest high dynamics in steady-state conditions, having a 
high cell death rate to control the size of the population. Furthermore, in contrast to 
naïve T cells, it was demonstrated that apoptosis contributes considerably to the Treg 
cell death. Together with the expression of certain markers, this fact supports the 
concept of Treg cells having an activated status. 
cFLIP proteins inhibit death receptor-mediated apoptosis and their role in the regulation 
of cell populations of the immune system has been proved.  A deletion of Cflar, the 
gene encoding all cFLIP isoforms, was performed specifically in Treg cells of mice in 
order to investigate their role in Treg homeostasis. As a consequence, Treg cells 
disappeared in the peripheral lymphoid organs and the mice developed a fatal 
autoimmune disease. Analysis of the gene expression of the cFLIP proteins revealed 
significant differences in the expression of the long isoform cFLIPL. This might explain 
the increased sensitivity to CD95-mediated apoptosis found in Treg cells compared to 
conventional T cells, despite the fact that both populations have identical expression of 
the CD95 receptor. Furthermore, Treg cells from the thymus of Cflar
Foxp3
 mice have 
increased sensitivity to CD95L stimulation, suggesting that cFLIP is important to 
protect Treg cells from CD95-mediated apoptosis. 
The study on the role of cFLIP in Treg homeostasis improved the knowledge about the 
regulation of the Treg cell population in order to understand better the behavior of the 
immune system. This would be beneficial for the development of immunomodulatory 
treatments to regulate the immune system in pathogenic scenarios such as autoimmune 
diseases or cancer. 
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2. Introduction 
2.1. Cell death 
Death of an organism can be defined as an irreversible event that implicates the 
impossibility to maintain homeostasis. Paradoxically, cell death is necessary for the life 
of multicellular organisms. Cell death can occur in a controlled manner, i.e. that a 
genetic program mediates cell death, hence programmed cell death. Complex organisms 
use cell death during development to build parts of the body, creating cavities, 
separating structures and eliminating useless components
1
. Immune cells are constantly 
generated and the organism needs to eliminate surplus cells in order to control the 
population size and to remove potential dangerous cells that might harm own 
structures
2–4
. Programmed cell death is also an effective method to erase infected cells 
and preserve the integrity of the neighboring healthy cells
5
. Programmed cell death 
contributes remarkably to the elevated replacement rate occurring in certain tissues like 
the skin and the gut, where thousands of cells are substituted by new cells every day
6,7
. 
The point-of-no-return within the cell death program is not clearly defined by a 
biochemical event. Nevertheless, the loss of the plasma membrane integrity and the cell 
fragmentation, including the nucleus, have been considered as morphological and 
molecular criteria to define the cell death
8
. Morphological appearance, enzymological 
activity, functional aspects and immunogenicity can be used as criteria to classify the 
different types of cell death. Necrosis is a type of cell death characterized by the loss of 
plasma membrane integrity and the cell collapse
9
. It is produced by physiochemical 
stress such as osmotic shock, mechanical stress, freeze and heat
10
. The release of the 
cytoplasmic content, due to the loss of the plasma membrane integrity, results in the 
induction of inflammatory responses caused by the detection of damage-associated 
molecular patterns (DAMP) by immune cells
11
.  
Apoptosis, a term coined in 1972
12
, is another type of cell death characterized by 
reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation 
(karyorrhexis), cell membrane blebbing and the formation of apoptotic bodies
8
. During 
the course of apoptosis, the plasma membrane maintains its integrity until the final 
stages and therefore the intracellular content remains inside the cell. This fact promotes 
the low immunogenicity of the process
8,13
. Moreover, apoptotic cells display “eat me” 
signals and release attractant substances in order to promote the localization and the 
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engulfment of the apoptotic bodies by phagocytes
14–16
. During this late phase, the 
elimination of cell debris occurs in a controlled environment of low immunogenicity to 
avoid inflammatory processes. The maintenance of the apoptotic cell cytoplasm within 
the plasma membrane, the release of anti-inflammatory mediators and the inhibition of 
pro-inflammatory cytokine production by the phagocytes avoid the activation of 
inflammatory response and tissue damage
17,18
.  
Autophagy is defined as the sequestration and degradation of cytoplasmic material 
within autophagosomes
19
. This regulated process is involved in the recycling of cell 
structures and organelles within the normal cell cycle program of the cell, promoting the 
cell survival
19
. Autophagy is important to degrade unwanted and damaged cell 
organelles and to re-use the subunits to build new structures as well as during cell 
starvation
19
. Autophagosomes are double-layered membrane vesicles containing 
degenerating organelles. The fusion of the vesicle with lysosomes causes the digestion 
of the inner content
19
. The regulation of autophagy is a very complex process involving 
the Atg proteins, phosphatidylinositol 3-kinase-I (PI3K-I), GTPases and the mammalian 
target of rapamycin (mTOR) pathway
20
. The autophagic machinery can be used also by 
the cell to capture and eliminate intracellular pathogens, which is also called 
xenophagy
21
. However, autophagy has a close relationship with cell death as well
22
. 
Nowadays there is not a consensus about if autophagy is a type of cell death or whether 
it is a process related with some stages of cell death. Some studies support the idea that 
autophagy participates in cell destruction by means of a massive autophagic 
vacuolization
23,24
. Others denominate “autophagic cell death” when the cell show 
similar features along with absence of chromatin condensation and the possibility of 
recovering upon withdrawal of the death-inducing stimulus
25–28
. Besides this 
controversy, the cross-talk between autophagy and apoptotic signaling has been clearly 
demonstrated. Autophagy can be induced by several pro-apoptotic signals, like some 
components of the extrinsic apoptosis pathway
29–32
. Conversely, autophagy can be 
suppressed by anti-apoptotic signals
33,34
. Thus, autophagy and apoptosis are two 
processes closely regulated and coordinated. 
Another type of cell death is cornification. This term refers to the process of envelope 
regeneration occurring in the skin epidermis
35,36
. Like apoptosis, cornification is a 
programmed cell death, but it presents numerous morphological and biochemical 
differences. It involves the transformation of corneocytes in keratinocytes containing 
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lipids and proteins, such as keratin and ceramides, necessary to provide to the skin layer 
certain attributes, like elasticity, mechanical resistance and water repellence
35,36
. 
Thanks to the scientific progress, it is possible to identify and classify additional types 
of cell death. Some of them share characteristics with other forms of cell death but have 
diverse features that allow them to be cataloged differently. That is the case for 
necroptosis, which is a programmed cell death dependent on the protein kinase RIP-1 
and sharing morphologic features with necrosis
37,38
. In addition to the above mentioned 
types of cell death, other atypical cell death modalities have been described, such as 
pyroptosis, pyronecrosis, entosis, paraptosis, mitotic catastrophe, anoikis, excitotoxicity, 
and wallerian degeneration
8
. 
 
 
 
 
Figure 1. Main types of cell death. Necrosis is characterized by the escape of 
the intracellular content to the extracellular space due to the loss of 
membrane integrity. In apoptosis the plasma membrane blebs forming 
apoptotic bodies that contain fragmented DNA and cell organelles. 
Autophagy is a mechanism by which the cell organelles are engulfed by a 
double membrane inside the cells and further degraded. 
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2.2. Apoptosis 
Apoptosis  is an evolutionary conserved process regulated by genes
39
. It is a complex 
and programmed cell death mechanism characterized by a controlled demolition of the 
cell architecture. Furthermore, apoptosis promotes cell debris removal under low-
immunogenicity conditions in order to avoid an unwanted immune response
8,13
.  
2.2.1. Morphological features 
During the course of apoptosis, different changes occur in the cell architecture. In the 
beginning, the cell becomes rounded up and retracts from surrounding cells followed by 
plasma membrane blebbing and finally the formation of apoptotic bodies
13
. The 
condensation and fragmentation of the nucleus is a remarkable hallmark of apoptosis. 
Caspase activity causes the proteolysis of the nuclear lamina and the collapse of the 
nuclear envelope
40
. Furthermore, the genomic DNA is fragmented followed by 
chromatin condensation
41
. Many important components of the cytoskeleton are targeted 
by caspases. Actin microfilament components such as actin and myosin are substrates of 
the protease activity
42–44
. Microtubular proteins, including tubulin, as well as 
intermediate filament proteins are also degraded by caspases
45–48
. The demolition of the 
cytoskeleton enables the rounding and the retraction from the surrounding cells and 
facilitates the membrane blebbing. Nevertheless, some intact actin filaments are 
required for the blebbing and the formation of apoptotic bodies
49
. Organelles are also 
affected by the apoptotic obliteration. Golgi apparatus and mitochondria are fragmented 
and packed into apoptotic bodies
50,51
. The pore formation in the outer mitochondrial 
membrane promotes the fragmentation of these organelles
52,53
. During late stages of 
apoptosis, chromatin is enveloped by endoplasmic reticulum (ER) and redistributed into 
apoptotic bodies
54
. Moreover, apoptosis affects drastically the protein synthesis 
machinery. Several transcription factors and multiple translation initiator factors and 
ribosomal proteins are affected by caspase activity
55
. Looking at the outer part of the 
cell, there are also changes in the plasma membrane during the apoptotic process. The 
organization of the membrane structure is altered. Molecules usually located in the inner 
leaflet of the membrane, like phosphatidylserine (PS), are exposed on the cell 
surface
15,16
. The molecule externalization enables the identification of apoptotic cells 
and promotes the engulfment by phagocytes
15,56,57
. The removal of the cell debris is the 
terminal phase of apoptosis. The collapse of the cell into apoptotic bodies facilitates the 
phagocytosis and the elimination of the apoptotic cell. In contrast to pathogen clearance, 
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apoptosis promotes a low-immunogenic environment, inducing immunosuppressive 
cytokine production, such as IL-10 and TGF-, to avoid undesirable immune responses, 
inflammation and tissue damage
17,18
. 
2.2.2. Caspases 
Apoptosis is orchestrated by members of a proteases family known as caspases 
(cysteine aspartic acid-specific proteases)
58,59
. Structurally, caspases are comprised of a 
pro-domain followed by a large and a short subunit and they can be cleaved after  
particular tetrapeptide motifs, where the last residue is an Asp
59
. This cleavage is 
necessary to achieve the caspase active form. Regarding their enzymatic activity, 
caspases have two catalytic conserved regions including the histidine residue in the His-
Gly motif and the essential cysteine residue in the Gln-Ala-Cys-X-Gly motif (where X 
denotes any amino acid)
60
. The caspase family can be divided into apoptotic and 
inflammatory members, according to their function. Caspases 1, 4, 5, 11, 12 belong to 
the inflammatory group whereas the apoptotic group can be subdivided into initiator 
and effector caspases
61
. Caspase 2, 8, 9 and 10, which are able to react upon apoptotic 
stimuli and are able to initiate the proteolytic processing of other caspases, are 
considered as initiator caspases
61
. On the other hand, caspase 3, 6 and 7, which are 
activated by other caspase proteases and are able to cleave the majority of substrates 
during apoptosis, belong to the effector caspases
61
. In steady-state conditions, caspases 
are present in the cell in an inactive form (zymogen). Upon apoptotic stimuli, the 
initiator caspases are cleaved and activated, leading to the initiation of the caspase 
cascade and the proteolytic activation of  the effector caspases
62
. The active caspase 
conformation consists of a heterotetramer originating from the cleavage of two pro-
caspase molecules resulting in two small and two large subunit arrangement
59,61
. 
Initiator caspases are present as monomers whereas effector caspases exist as pre-
formed dimers in the cell
61
. The prodomain region includes motifs, like the caspase 
recruitment domain (CARD) or the death effector domain (DED), that facilitates the 
recruitment of caspase units
62
.  
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Figure 2. Caspases are a family of proteases that cleave their substrates after specific 
tetrapeptide motifs (P4-P3-P2-P1) where P1 is an Asp residue. All the caspases have similar 
structures. They are formed by a pro-domain sequence that participates in the recruitment of 
initiator caspases. So far, two pro-domains have been identified, the caspase recruitment 
domain (CARD) and the death effector domain (DED). The caspases can be divided into two 
functional groups, the initiators, which are able to auto-activate and cleave other caspases, and 
the effectors, which are activated by other caspases and cleave the majority of substrates. A 
broad group of caspases participates in apoptosis; however, there is a group involved in 
inflammatory responses produced by the innate immune system. Caspase 12 does not contain 
the catalytic region within its sequence. Interestingly, a group of African individuals express 
the complete form of caspase 12 containing the catalytic site. These individuals show higher 
susceptibility to inflammatory diseases. Adapted from Taylor et al. 2008
13
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2.2.3. BCL-2 family 
Apoptosis can be mediated by the intrinsic pathway, also called B-cell lymphoma-2 
(BCL-2)-regulated or mitochondrial pathway. The induction of such mechanism is 
caused by developmental cues, cytotoxic injury and cellular stress, like DNA damage, 
viral infection, low ATP levels, pH variations, reactive oxygen species (ROS) massive 
production or growth-factor deprivation
63
. BCL-2 family proteins regulate tightly this 
pathway. The members of this family are classified into three groups. BCL-2-associated 
X protein (BAX), BCL-2-antagonist/killer-1 (BAK) and BCL-2-related ovarian killer 
(BOK) are included in the group of effector proteins
64
. BAX and BAK produce the 
permeabilization of the outer mitochondrial membrane (OMM) causing the release of 
apoptogenic molecules (such as cytochrome c and DIABLO/SMAC) from the 
mitochondria, promoting the activation of caspases
63
. In healthy conditions BAK 
resides on the OMM, inactivated by the binding with myeloid cell leukaemia 1 (MCL-
1) and B-cell lymphoma-extra-large protein (BCL-XL)
65,66
, whereas BAX and BOK are 
located at the cytosol
67,68
. Cytosolic BAX masks its hydrophobic C-terminal membrane 
anchor in the BH-3 binding pocket
67
. Upon apoptosis induction, BAX proteins 
translocate to mitochondria and are inserted into the OMM via the C-terminal anchor
67
. 
In addition to MCL-1 and BCL-XL, the group of anti-apoptotic proteins is completed 
by BCL-2, BCL-2-like-2 (BCL-W), BCL-B (also called BCL-2L10), and BCL-2-related 
protein A1A (A1A, also named BCL-2A1)
64
. A third group of the BCL-2 family, 
consisting in BCL-2 antagonist of cell death (BAD), BH3-interacting domain death 
agonist (BID), BCL-2-interacting killer (BIK), harakiri (HRK), BCL-2-like-11 (BIM), 
Bcl-2-modifying factor (BMF), NOXA and PUMA (BCL-2 binding component-3), 
have a conserved BH-3 domain that can bind to the group of anti-apoptotic members, 
producing the repression of their interaction with the effector proteins BAX and BAK
64
.  
2.2.4. Death receptors 
The extrinsic pathway, also named death receptor-mediated apoptosis pathway, is 
initiated by signals coming from death receptors located on the cell surface. The death 
receptors belong to the tumor-necrosis factor (TNF) receptor superfamily that includes 
TNF receptor 1 (TNFR1), CD95 (alternatively called FAS or APO-1), TNF-related 
apoptosis-inducing ligand receptor 1 (TRAILR1), TRAILR2, death receptor 3 (DR3) 
and DR6. These receptors have the presence of a death domain (DD) motif in their 
cytoplasmic tail in common and they can be triggered by their respective ligands, 
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namely TNF, CD95 ligand (CD95L, also named FASL) and TNF-related apoptosis-
inducing ligand (TRAIL)
69–72
.  
2.2.5. Signaling pathways of apoptosis 
2.2.5.1. The intrinsic pathway  
During intrinsic apoptosis induction, anti-apoptotic proteins are degraded
65,73
 or their 
interaction with BAX or BAK is disrupted by BH3-only proteins
66
. Once BAX is 
inserted in the OMM or BAK is free of inhibitory proteins, the pore formation in the 
OMM is accomplished. This causes the release of apoptogenic molecules from the 
mitochondria to the cytosol, facilitates the fragmentation of the mitochondria and finally 
the cellular apoptosis takes place
63
. Some studies have demonstrated that the presence 
of either BAX or BAK is sufficient to make the intrinsic pathway functional, whereas 
the double deletion of these proteins abolishes the apoptotic pathway
74
. Nevertheless, 
the absence of one of these proteins produces some abnormalities, indicating that the 
functional redundancy is not complete
74–76
.  Regarding the pro-apoptotic protein BOK, 
its role is poorly understood so far and recent studies suggest its importance on tumor 
suppressor
68
 or restrict its apoptotic activity to certain tissues
74
. 
One of the consequences of the OMM permeabilization is the escape of cytochrome c to 
the cytoplasm. Cytochrome c is a component of the electron transport chain and it is 
essential in the mitochondrial energy production
77
. Besides its role on the cellular 
metabolism, the release of this molecule to the cytoplasm promotes apoptosome 
formation. This complex is comprised of apoptotic protease activating factor 1 (APAF-
1), cytochrome c and ATP/dATP. Cytosolic cytochrome c binds to APAF-1 molecules, 
which are usually inactive in the cytoplasm, facilitating the binding of dATP to APAF-
1
78
. Simultaneously, procaspase-9 units are recruited to the APAF-1 CARD.  Once the 
apoptosome is assembled, the cleavage of the initiator caspase-9 takes place and the 
caspase cascade is initiated, triggering apoptosis
79
. This mechanism can be repressed by 
another group known as inhibitor of apoptosis proteins (IAPs), such as X-linked 
inhibitor of apoptosis protein (XIAP). They  regulate apoptosis downstream of 
apoptosome assembly, binding to and inhibiting effector caspases
80
. This group of anti-
apoptotic proteins can be counterbalanced by another element released from the 
mitochondria known as DIABLO/SMAC
81,82
. This protein binds directly to IAPs 
preventing their binding and inhibition of effector caspases
83
.  
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2.2.5.2. The extrinsic pathway  
The signal transduction from the death receptors initiates the formation of the death-
inducing signaling complex (DISC)
70
. The CD95 and TRAILR DISC consist of 
oligomerized CD95/TRAILR, Fas-Associated Death Domain (FADD) and pro-caspase 
8 (also known as FLICE) or pro-caspase 10, which is exclusively present in humans
70,84
. 
DISC interactions are based on homotypic contacts. The DD of CD95/TRAILR 
interacts with the DD of FADD and the DED of FADD interacts with the DED of the 
pro-caspases
70
. The assembly of the DISC results in the recruitment and auto-
proteolytic activation of the initiator caspases, consisting of a double cleavage of the 
pro-caspases. The resulting activated heterotetramer from pro-caspase 8, consisting of 
two large subunits (p18) and two small subunits (p10), is released into the cytosol 
initiating the caspase cascade and finally causing cell death
70
. The activation of 
apoptosis mediated by the heterotetramer of caspase 10, in absence of caspase 8, is still 
controversial
70,85
.  
On the other hand, TNFR1 signaling mechanism is different because it results in the 
formation of 2 complexes. Signaling complex I is formed at the membrane upon 
Figure 3. BCL-2 protein family tightly 
regulates the intrinsic pathway of apoptosis. 
Within this family, the group of anti-apoptotic 
proteins (BCL-2, BCL-XL, BCL-W, A1A and 
MCL-1) inhibits the pore formation on the outer 
mitochondrial membrane mediated by the pro-
apoptotic proteins BAX and BAK. Another 
group of the BCL-2 family (BID, tBID, PUMA, 
BAD, and NOXA) represses the anti-apoptotic 
proteins promoting the mitochondrial 
permeabilization and facilitating the release of 
cytochrome c and DIABLO (also known as 
SMAC). The apoptosome is assembled by the 
cytoplasmic cytochrome c together with APAF-
1 and pro-caspase 9 units. This complex 
initiates the activation of the caspase cascade 
and therefore the cell apoptosis. IAPs located in 
the cytoplasm can repress caspase activity and 
block apoptosis. The inhibition of IAPs by 
cytoplasmic DIABLO facilitates the apoptotic 
process.  
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TNFR1 stimulation and consists of TNF, TNFR1, receptor interacting protein (RIP-1), 
TNFR1-associated death domain protein (TRADD) and TNFR-associated factor 
(TRAF-1/2). This complex may activate nuclear factor kappa B (NF-B) through 
inhibitor of B kinase (IKK) complex recruitment and may activate (c-Jun N-terminal 
kinases) JNK in a TRAF-2 dependent manner
86
. Complex I can translocate into the 
cytoplasm and recruit FADD and procaspase 8/10, forming the complex II, also called 
traddosome
86
. This complex is able to activate the caspase cascade and initiate 
apoptosis. The efficiency of complex II formation and its interaction with inhibitory 
proteins allows for the activation of the survival or the death program in the cell
86
. 
 
 
 
 
 
Figure 4. The death-inducing signaling complex (DISC) consists of death receptor 
oligomerized subunits, adaptor protein FADD and pro-caspase 8/10 recruitment, 
upon ligand stimulation. The interaction between the death receptor and FADD is 
mediated by death domain (DD) motifs whereas the interaction between FADD and 
pro-caspase is due to death effector domain (DED) contacts. The DISC assembly 
results in the cleavage and activation of the initiator caspases. Adapted from 
Krammer et al. 2007
87
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2.2.5.3. The crosstalk between the pathways 
The extrinsic pathway is able to interact and activate the machinery of the intrinsic 
apoptosis. High levels of DISC formation promote high amounts of active caspase 8, 
which further trigger effector caspases. This mechanism is characteristic of type I 
cells
87
. However, when the amounts of DISC are not able to trigger the activation of 
effector caspases, the little amounts of caspase 8 need to implement an amplification 
loop that consists of the cleavage of BID
87,88
. The truncated form of BID (tBID) 
produces BAX and BAK aggregation on the OMM, releasing cytochrome c to the 
cytoplasm and producing the subsequent activation of apoptosis
88,89
. Type II signaling 
can be repressed by anti-apoptotic BCL-2 family members, such as BCL-XL and BCL-
2, whereas they are dispensable to block type I-mediated apoptosis since this pathway 
bypasses the mitochondrial mechanism
88
. 
2.2.5.4. The granzyme B pathway 
Cytotoxic T lymphocytes (CTL) and Natural Killer (NK) cells of the immune system 
can induce apoptosis in order to remove virus infected cells and tumor cells. To 
eliminate them, CTLs and NK cells release cytolytic granules containing pore-forming 
proteins, such as perforin, and serine proteases, known as granzymes
90
. It has been 
demonstrated that this protein is able to cleave the initiator caspase 8 and the effector 
caspase 9, causing cell apoptosis
91,92
. Additionally, granzyme B can cleave BID and 
promote its translocation to the mitochondria and the subsequent OMM 
permeabilization by BAX and BAK, inducing the formation of the apoptosome and the 
consequent caspase cascade activation
93,94
.  
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Figure 5. Apoptosis pathways. Cell stress promotes the triggering of the intrinsic pathway. The 
activation of BH3-only proteins inhibits the anti-apoptotic BCL-2 proteins, facilitating the pore 
formation in the outer mitochondrial membrane by BAX and BAK. In consequence, 
cytochrome c is released to the cytoplasm producing the assembly of the apoptosome, 
consisting of APAF-1 subunits, cytochrome c molecules and pro-caspase 9. The formation of 
this complex results in the cleavage of caspase 9 and the further activation of effector caspases. 
The engagement of death receptors causes the recruitment of adaptor proteins, like FADD, 
which facilitates the recruitment of pro-caspase 8 molecules, leading to the formation of the 
death-inducing signaling complex (DISC). This recruitment triggers the activation of caspase 8, 
which is able to activate effector caspases. Low levels of active caspase 8 can crosstalk with the 
intrinsic pathway through the cleavage of BID. The truncated form of BID (tBID) promotes the 
pore formation and the further permeabilization of the mitochondria. The entrance of granzyme 
B through the pore formed on the plasma membrane by perforin, both released by cytotoxic 
cells, initiates apoptosis by effector caspases cleavage as well as BID proteolysis. Adapted 
from Krammer et al. 2007
87 
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2.2.6. The FLICE-inhibitory proteins 
Cellular caspase 8 (FLICE)-like inhibitory protein (cFLIP) is an anti-apoptotic regulator 
that suppresses death-receptor mediated apoptosis. Originally, FLIP proteins were 
identified as viral gene products, called vFLIPs, produced by several -herpesviruses. 
These proteins contain DEDs that are able to interact with caspases
95,96
. After the 
discovery of these viral proteins, the cellular homologue was identified and named 
cFLIP (also known as CASH, Casper, CLARP, FLAME, I-FLICE, MRIT and 
usurpin)
97–104
. So far, the expression of three different splice variants has been 
identified. The longest isoform of 55 kDa, known as cFLIPL, contains two DED and a 
catalytically inactive caspase-like domain
61,97
. The C-terminus of cFLIPL resembles the 
structures of caspase 8 and 10, but lacks a functional caspase domain
105
. The lack of 
catalytic activity is due to the substitution of several amino acids, particularly the 
cysteine residue in the catalytic domain
105
. Heterodimerization of caspase 8 with cFLIPL 
produces a partial processing of caspase 8 generating the p10 fragment of caspase 8 and 
a p12 fragment from cFLIPL. The product of this combination results in a limited 
activity of caspase 8
106
. Furthermore, cFLIPL has a caspase 8-cleavage site (Asp-376) 
independent of death receptor ligation
107
. This interaction of cFLIPL with caspase 8 
produces the formation of the fragment variant p43-cFLIP
107
. An alternative function of 
the early caspase 8 cleavage product from cFLIPL p43 is the activation of the NF-B 
pathway. Concretely, p43 can efficiently interact with RIP-1 and TRAF-2 and initiate 
the activation of the NF-B pathway108,109. 
Moreover, two short isoforms have been described, the 26 kDa cFLIPS form and the 24 
kDa cFLIPR form
110,111
. cFLIPS is present in human but not in mice and consists of two 
DED followed by a ~20 aminoacids sequence,  relevant for the ubiquitylation and  the 
further proteasomal degradation
111,112
. Similarly, cFLIPR consists of two DED. This 
isoform, present in human and mouse, was originally identified in the Raji B cell line
110
. 
In human, the expression of the short isoforms is decided by a single nucleotide 
polymorphism (SNP) in a particular splice site
113
. 
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Death receptor-mediated cFLIP inhibition is regulated by the interaction of the DED of 
these molecules with the adaptor protein FADD and, in consequence, cFLIP proteins 
compete with pro-caspase 8 recruitment at the DISC level. The short isoforms of cFLIP 
are considered full inhibitors of caspase 8 recruitment
97,106
, whereas the function of 
cFLIPL is more complex. cFLIPL can compete with caspase 8 recruitment and therefore 
repress the initiation of apoptosis
105
. However, it can also form a heterodimer with 
caspase 8 through the interaction of both caspase-like domains, resulting in a limited 
apoptotic activity
105
. Regarding this dual function, it has been reported that low levels of 
cFLIPL promote apoptosis by caspase 8 processing, whereas high levels of cFLIPL 
repress apoptosis
105
. In addition, the processed fragment p43FLIP recruits efficiently 
RIP-1 and TRAFF-2 and, after caspase 8 interaction, can activate the NF-B 
pathway
114,115
. 
Figure 6. Three isoforms of cellular caspase 8 (FLICE)-inhibitory protein 
(cFLIP) are known: cFLIPlong (cFLIPL) cFLIPshort (cFLIPS) and cFLIP Raji 
(cFLIPR). The death effector domains (DED), the catallyticaly inactive 
caspase-like domains p20 and p12 as well as the cleavage sites are shown. 
cFLIP cleavage products includes p43-FLIP and p22-FLIP. Adapted from 
Krammer et al. 2007
87 
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2.2.7. The role of the FLICE-inhibitory proteins (cFLIP) in the immune system 
cFLIP is expressed in a wide variety of cells, such as myocytes, keratinocytes, neurons, 
endothelial cells, as well as in cells of the immune system, including hematopoietic 
stem cells, dendritic cells (DCs), macrophages, B cells and T cells
116–123
. These 
molecules are very important not only in cell survival but also in the activation of 
certain functions and developmental stages of cells in the immune system. For instance, 
low cFLIP levels have been reported in monocytes, whereas macrophages and immature 
DCs show high levels
122,124
. Since CD95L stimulation upregulates the production of 
several cytokines in these cells, they need to be protected against CD95L-mediated 
apoptosis
121,122,125
. Furthermore, cFLIP seems to be important in the activation of 
different pathways, like NF-B, through CD95L stimulation126. cFLIP has also an 
important  role in B and T cell development and function. In the case of the B cells, 
CD40 and antigen-receptor stimulation upregulates cFLIP and protects these cells from 
CD95-mediated cell death
127,128
. The function of cFLIP seems to be important in the 
Figure 7. The homodimerization of caspase 8 results in the auto-proteolytic and trans-
proteolytic cleavage initiating the activation of this caspase. The caspase 8-cFLIPL 
interaction leads to the formation of the p10 and p12 respective fragments and a limited 
apoptotic activity. On the other hand, the interaction of caspase 8 and cFLIPS inhibits 
completely the activation of caspase 8. Finally, the caspase 8-p43FLIP interaction 
results in the activation of the NF-B pathway, supported by the recruitment of RIP-1 
and TRAF-2. Adapted from Budd et al. 2006
123
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germinal centers, where B cells initiate the caspase machinery and, upon CD40 
stimulation and DC contact, achieve the apoptosis inhibition
129
. Similarly, T cells 
elevate cFLIP expression upon T cell receptor (TCR) stimulation
130
. This fact is linked 
to the T cell activation. It has been demonstrated that Jurkat T cells overexpressing 
cFLIPL show an elevated NF-B pathway activation upon TCR stimulation. As a 
consequence, these cells produce more interleukin 2 (IL-2) than wild-type Jurkat 
cells
126
. Furthermore, cytokines, such as IL-2, IL-4, and IL-12, can also modulate the 
gene expression of cFLIP
131,132
. Interestingly, it has been shown that IL-4 negatively 
regulates cFLIP in T cells
131
. This cytokine promotes T helper 2 (Th2) differentiation 
from naïve T cells, and consistent with the cFLIP expression, the differentiated cells 
have higher caspase activity
133
. 
An indirect way to decipher the impact of the cFLIP function in the cells is to study the 
effects of its deletion in vivo. Since the deficiency of cFLIP is embryonically lethal in 
mice
134
, cFLIP has been deleted specifically in T cells. The result of this deletion 
revealed a reduction of the -T cell compartment due to a proliferation and survival 
defect
135,136
. cFLIP-deficient thymocytes and cFLIP-deficient mature T cells, both 
manifest an impaired viability compared to the respective wild-type cells. Additionally, 
the requirement of cFLIP for normal proliferation in response to TCR stimulation was 
proved
135
. Looking more in detail into the specific role of the different isoforms, all 
cFLIP variants can repress death receptor-mediated apoptosis by preventing caspase 8 
cleavage
95,105,106
. In addition, cFLIPL has the capacity to form p43-FLIP-caspase 8 
complexes, which are able to activate the NF-B pathway and, in consequence, improve 
the T cell survival and activation competence
114,115
. 
2.3. Apoptosis and immune homeostasis 
One of the main functions of the immune system is to defend the organism against 
harmful pathogens as well as to clear unwanted and dangerous cells. Apoptosis is an 
important mechanism to develop these functions. On one hand, several cells of the 
immune system induce apoptosis to eliminate infected or cancer cells. There are 
particular cell types specialized in this task, like CTL and NK cells
137,138
. They can 
induce apoptosis by means of the granzyme B pathway, activating death receptors 
located on the surface of the undesired cell, or induce cell death by cytokine-mediated 
cytotoxicity
137,138
. Another scenario where apoptosis has a significant relevance is the 
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regulation of the immune homeostasis by controlling the cell number of the different 
populations. Normally, under steady-state conditions, the immune system remains in a 
surveillance mode. Only when there is a threat, the cells of the immune system are 
activated and begin to proliferate to act against the threat. Following the resolution, the 
system needs to return to the previous situation to avoid damage to its own tissues and a 
waste of energy. To do this, many cells involved in eliminating the threat must 
disappear and therefore apoptosis becomes important to recover towards homeostasis 
again. For instance, activation-induced cell death (AICD) is crucial to reduce the 
population of T cells after clonal expansion. Resting T cells are resistant to CD95-
mediated apoptosis due to low receptor expression
139
. Upon antigen encounter, these 
cells proliferate, get activated and upregulate CD95
139
. Despite this fact, T cells remain 
resistant to death receptor-mediated apoptosis favored by the presence of the anti-
apoptotic protein cFLIPS
140,141
. After antigen disappearance, cFLIPS is downregulated 
and the T cells become sensitive to CD95-mediated apoptosis
141
. Only few cells that 
result from clonal expansion maintain high levels of the anti-apoptotic protein, 
promoting the survival of memory cells
142
. Thus, death receptor-mediated apoptosis has 
been demonstrated effective to regulate the clonal expansion and deletion of T cells. In 
addition, the intrinsic pathway also plays a role in the shut-down of the immune 
response. The BH3-only proteins mediate the activation of the intrinsic machinery of 
apoptosis upon cytokine withdrawal
143
. That represents an additional mechanism that 
ensures the reduction of the lymphocytes after the cytokine downregulation as a 
consequence of the antigen clearance
144
.  
 
          
Figure 8 Modulation of both effector 
and suppressor cell populations is 
crucial to maintain the immune 
homeostasis.  Increase of effector cells 
might result in chronic inflammation 
and autoimmunity, whereas increase of 
suppressor cells supposes vulnerability 
against pathogens and tumor cells.  
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2.3.1. Function of immune system 
The regulation of the size of different cell subsets of the immune system is crucial for 
its homeostasis. In healthy conditions, the immune system is resting, vigilant and able to 
recognize a threat, get activated and eliminate the threat.  Besides physicochemical 
barriers, defense against threats occurs at two different, but connected levels. Firstly, the 
immune system has specialized populations that are able to recognize specific 
molecules like the pathogen associated molecular patterns (PAMP) of microorganisms 
or “kill-me” signals from unwanted cells145–147. As a result, the immune system is able 
to react quickly to the threat. Moreover, some of these cells, such as DCs and 
macrophages are capable to process and present antigens coming from undesirable cells 
or pathogens
148
. Cells of the adaptive immune system recognize these antigens and are 
able to mount a second line of defense against the threat. A stochastic rearrangement of 
the gene segments encoding immunoglobulin (Ig) and TCR / chains give the 
capability to T and B cells to have a quasi-unlimited receptor repertoire against any 
antigen
149
. Moreover, another advantage of the adaptive immunity is that a group of 
antigen-experienced cells remains as memory cells after the antigen clearance, to ensure 
a quick and effective response against a second encounter with the same threat
150,151
.  
2.3.2. Lymphocyte development 
Due to the random genetic reorganization of the / TCR and Ig chains, any antigen is 
susceptible to be recognized by these cells, including self-antigens and antigens from 
the food or the microflora
152
. In such circumstances, the immune system needs 
mechanisms to tolerate those non-harmful antigens, in order to preserve the immune 
homeostasis and avoid the development of allergic reactions or autoimmunity. Given 
that autoantibody producing B cells appear during early stages of their development, the 
requirement of a mechanism to avoid or ameliorate the emergence of these cells is 
essential
153
. These cells are forced to undergo a process of receptor editing, to enter into 
an anergic, i.e. unresponsive, state or undergo apoptosis
154,155
. Furthermore, autoreactive 
B cells can escape from these checkpoints or newly arise from nonautoreactive B cells. 
To prevent the progression of these cells, there are similar mechanisms to regulate the 
malfunction of the B cells in peripheral organs
154,156
. 
Analogous to B cells, mechanisms to prevent T cell-derived autoimmunity are needed. 
Firstly, an “educational program” for T cells occurs in the thymus. This process of 
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central tolerance begins when the cell precursor enters in the thymus
157
. At this stage, 
the thymocytes do not express neither the co-receptors CD4 nor CD8
157
. Then, the 
stochastic rearrangement of the  and  genetic segments takes place, the pre-receptor 
is assembled and both co-receptors are expressed, giving the conformation of double 
positive (DP) to the thymocytes
158,159
. In this stage, the TCR interacts with a self-
antigen—MHC complex from DCs and thymic epithelial cells (TEC). The self-peptides 
presented are either exported by migratory DCs or generated by TECs thanks to the 
ability given by the transcription factor AIRE to generate self-tissue proteins. If the 
TCR-MHC interaction is impaired, the cell undergoes programmed cell death in a 
process known “death by neglect”. More than 90% of the thymocytes die through that 
mechanism due to the expression of “useless” TCR. If the TCR-MHC engagement is 
made correctly, the thymocyte downregulates one of the co-receptor becoming CD4
+
 
helper or CD8
+
 cytotoxic cell. Additionally, the tolerance to self-antigen is checked 
from DP to single positive stage. The TCR interacts with self-antigen-MHC complexes 
continuously in the thymus. If one of these interactions happens with high affinity, then 
the thymocyte is deleted in a process called “negative selection”. In the end, only 
thymocytes with a correct engagement and low affinity for self-antigens reach the 
“positive selection” stage and migrate from the thymus to the periphery. This 
mechanism aims to ensure that functional but not dangerous T cells are generated. 
2.3.3. Treg development 
Since negative selection does not ensure the complete elimination of all the autoreactive 
T cells, some potential harmful cells can escape from the thymus. Consequently, there is 
a second level of regulation known as peripheral tolerances that counterbalance the 
occasional breakout of autoreactive T cells, contributing to keep immune 
homeostasis
160
. Apart from the secretion of suppressive cytokines in certain tissues, the 
main mediators of the peripheral tolerance are the regulatory T cells (Tregs)
161,162
. This 
cell type represents about 10 % of the total CD4
+
 compartment in the periphery and they 
express the interleukin 2 receptor  chain (CD25) and the forkhead box P3 transcription 
factor (Foxp3)
162,163
. Tregs originate in the thymus, like other -T cells. However, 
during the thymic selection process, Tregs manifest higher TCR-peptide-MHC affinity 
than positive selected T cells
164–166
. This fact would entail the elimination of the Tregs 
by negative selection. Conversely, these cells are reprogrammed to avoid the cell death 
and become suppressive cells
167
. 
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In addition, the differentiation under appropriate stimuli of naïve T cells to Tregs 
represents another source of Treg generation. The cytokine transforming growth factor 
beta (TGF-) results crucial to achieve this T cell polarization to induced Tregs (iTregs) 
in the periphery
168
. 
 
 
 
 
 
 
 
 
 
Figure 9. Cell fate during thymic selection is determined by the interaction strength between 
the TCR and the peptide-MHC complex. Deficient interactions result in the death of the cell 
through a mechanism known as death by neglect. Moreover, interactions trigger the negative 
selection, controlled by the pro-apoptotic protein BIM, which promotes cell apoptosis to 
avoid the development of potential autoreactive cells. Weak TCR-peptide-MHC interactions 
are needed to protect the thymocytes, promoting the positive selection and the development of 
naïve T cells. The development of Treg cells occurs within a range of interactions between the 
positive and negative selection. Therefore, Treg cells present a TCR repertoire with higher 
affinity to self-peptides compared to naïve T cells, sharing an affinity range with the potential 
autoreactive cells. Adapted from Klein et al. 2014
160
 
  
Figure 10. Thymus-derived Treg 
cells (also called “natural Tregs”) 
initiate the expression of the 
transcription factor Foxp3 
mediated by cytokine signals 
through thymic epithelial cells 
interactions as well as signals from 
the common cytokine-receptor- 
chain subunit. Alternatively, Treg 
can develop in the periphery from 
naïve T cells through antigen 
encounter and IL-2/TGF- 
stimulation. Adapted from Hühn et 
al.2009
234
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Strikingly, dysfunction of Treg cells leads to autoimmune diseases
169
. The complete loss 
of function  of the Tregs causes in humans the idiopathic polyendocrinopathy X-linked 
(IPEX) syndrome, characterized by a fatal systemic autoimmune disease
170
. Moreover, 
Treg cell depletion or the presence of a nonfunctional transcription factor Foxp3 in the 
Treg cells generates a similar phenotype in mice, which is called scurfy
171–173
. These 
mice present runting, scaly skin, ears and eyelids, splenomegaly, lymph nodes 
enlargement and premature death
174
. 
2.3.4. Treg function 
Tregs have different mechanisms of action to mediate the suppression. They can secrete 
inhibitory cytokines, such as TGF-, IL-10, and IL-35 to diminish the effector activity 
of the immune system
175–178
. Moreover, Tregs have cytolytic activity inducing apoptosis 
in a perforin-,  granzyme-A- and granzyme-B-dependent manner
179
. For instance, Tregs 
can suppress B cell function by killing these cells via apoptosis
180
. Tregs use also 
metabolic disruption mechanisms to inactivate or kill other effector cells. On the one 
hand, Tregs consume IL-2 by the expression of CD25 and compete with other cells for 
this cytokine
163
. IL-2 reduction causes a deprivation of this resource in activated T cells 
that produces the activation of the intrinsic apoptosis in these cells
181,182
. On the other 
hand, release of adenosine nucleosides represses T cell functions through the activation 
of the adenosine receptor 2A, it promotes TGF- secretion and inhibits IL-6 
production
183,184
. This cytokine blocks Treg generation and polarizes naïve T cells to T 
helper (Th) 17 differentiation
185
. Therefore, IL-6 repression facilitates an 
immunosuppressive environment instead of the development of an inflammatory 
process. In addition, Tregs can transfer the inhibitory second messenger cyclic 
adenosine monophosphate (cAMP) through gap junctions into effector T cells
186
. 
Furthermore, another cell target of the Treg suppression are the antigen-presenting DCs, 
which are mediators of the T cell activation
187
. Tregs restrain DCs through the 
lypmphocyte-activation gene 3 (LAG3)-MHC and the cytotoxic T-lymphocyte antigen 
4 (CTLA4)-CD80/CD86 interaction
188–190
. Besides the inhibition of the DC function 
and maturation, this mechanism produces the release of indoleamine 2,3-dioxygenase 
(IDO) by the DCs, which is a potent inhibitor of the T cell effector function
191
. 
  
23 
 
 
 
 
 
 
2.6 The control of the regulatory T cell homeostasis 
2.3.5. Treg homeostasis 
The suppressive function of the Tregs constitutes a key factor in the balance of the 
immune homeostasis. The Treg population is regulated by different mechanisms 
contributing to the Treg homeostasis and, in consequence, influencing in the regulation 
of the immune system. In contrast to initial studies indicating that Tregs manifest an 
anergic condition
192,193
, Tregs are in a semi-activated state, probably due to the TCR 
self-reactivity, which produces an elevated basal proliferation rate compared to 
conventional T cells (Tcons)
194–197
. The high proliferation of the Tregs needs to be 
counterbalanced by cell elimination mechanisms in order to keep the size of the 
population. Recent reports connect Treg cell death to the intrinsic pathway of apoptosis. 
The transcription factor Foxp3 upregulates the BH3-only proteins BIM and PUMA, 
promoting the inhibition of BCL-2 anti-apoptotic proteins and consequently, facilitating 
the permeabilization of the mitochondria, initiating the intrinsic pathway of 
Figure 11. A. Release of inhibitory cytokines, such as TGF-, IL-10 and IL-35 repress the 
activity of effector cells. B. Induction of granzyme-mediated apoptosis produces the cytolysis of 
target effector cells. C. Metabolic disruption includes IL-2 consumption, promoting the apoptosis 
initiation due to cytokine deprivation. Moreover, adenosine and cAMP production by Treg cells 
causes inhibition of effector cells and immunosuppression. D. Modulation of the function and 
maturation of dendritic cells (DC) by CTLA-4-CD80/86 and LAG-3-MHC interactions are 
effective methods to mediate immunosuppression as well as the induction of the production of 
the immunosuppressive molecule indoleamine 2,3-dioxygenase (IDO) by DCs. Adapted from 
Vignali et al.2008
235
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apoptosis
198
. Foxp3-promoted Treg lethality can be reverted by common gamma chain 
(c)-mediated cytokine signals198. IL-2 signaling upregulates the anti-apoptotic protein 
MCL-1 in peripheral Tregs, which counterbalances the pro-apoptotic protein function of 
BIM
199
. Thus, the IL-2-mediated regulation of the MCL-1-BIM axis controls the 
activation of the intrinsic pathway of apoptosis and therefore it plays an essential role in 
the Treg homeostasis.  
  
 
 
 
 
 
 
Figure 12. Intrinsic pathway controls Treg apoptosis, which is regulated by 
the BCL-2 family members. IL-2 counterbalances the pro-apoptotic function 
of Foxp3, which promotes the inhibition of MCL-1 through the pro-apoptotic 
protein BIM. The repression of MCL-1 facilitates the permeabilization of the 
mitochondria and the initiation of the intrinsic pathway of apoptosis. 
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2.4 Aims of the thesis 
Regulatory T cells are able to suppress the immune response and, therefore, play a key 
role in the maintenance of immune homeostasis
200
. They represent a part of the balance 
that counteracts the effector response of the immune system. A shift towards the 
suppressor part versus the effector part supposes a weakening of the immune response, 
turning the organism more susceptible to infections or tumor development
201,202
. On the 
other hand, the inverse situation produces a hyperactivity of the immune system 
facilitating the development of inflammatory processes and autoimmune diseases
203,204
. 
Thus, a strict regulation of the size of the populations on both sides of the balance is 
necessary to keep immune homeostasis. Proliferation and cell death are two factors 
controlling the size of the population.  Previous studies reported that Treg cells exhibit a 
high proliferation and apoptosis rate compared to conventional T cells, indicating the 
high dynamics of the suppressive cell type
196,197,200
. Furthermore, the apoptotic 
mechanisms that regulate the Treg apoptosis have been investigated. The studies reveal 
that the transcription factor Foxp3 promotes apoptosis in the Tregs by means of the pro-
apoptotic protein BIM
198
. This mechanism is dampened by the IL-2-mediated 
upregulation of the anti-apoptotic protein MCL-1
199
. However, to date, all investigations 
give emphasis on the regulation of the Treg apoptosis by the intrinsic pathway, 
neglecting a possible contribution of the extrinsic pathway to the apoptosis of this cell 
type. The aim of this thesis was to address whether the extrinsic pathway of apoptosis is 
relevant in the regulation of the Treg apoptosis. The first part of the thesis aimed to 
demonstrate, by ex vivo analyses, that the Treg cells display a higher cell death rate 
compared to conventional T cells and by which death mechanism Treg cells die. 
Additionally, the role of the anti-apoptotic protein cFLIP in Treg cell homeostasis was 
investigated by deleting the cFLIP-encoding gene specifically in murine Treg cells. 
Furthermore, the impact of the different death ligands and the contribution of the cFLIP 
isoforms on death receptor-mediated Treg cell death were studied. 
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3. Materials 
3.1. Chemicals 
If not mentioned otherwise, chemicals used to perform the experiments were purchased 
from Roth (Karlsruhe, Germany), Sigma Aldrich (Munich, Germany) or Merck 
(Darmstadt, Germany). 
 
3.2. Cell culture material and devices 
Cell culture work was performed using 6-well, 12-well, 24-well and 96-well plates 
obtained from NUNC - Thermo Fisher scientific (Rochester, USA). Sterile 10 l, 200 l 
and 1000 l filtered pipette tips were obtained from Starlab (Ahrensburg, Germany). 
Greiner bio-one (Frickenhausen, Germany) provided 15 ml and 50 ml conical tubes. 5 
ml, 10 ml and 25 ml pipettes were purchased from Sterilin – Thermo Fisher Scientific 
(Rochester, USA). 20 m and 45 m sterile syringe filters were provided by Becton 
Dickinson (Heidelberg, Germany) and Millipore (Waltham, USA). 
Cells were settled down using a 5810R centrifuge from Eppendorf (Hamburg, 
Germany) and were handled in a Sterile Guard III from The Baker Company (Sanford, 
USA). HERAcell 240i (Thermo Scientific) incubators were used for cell culture at 
37°C, 5% CO2 and 95% air humidity. Cell number was determined using a Cellometer 
Auto T4 by Nexcelom Bioscience (Lawrence, USA). 
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3.2.1. Cell culture media and supplements 
Reagent Lot. No. Order No. Company 
RPMI 1640 1003068 41965 GIBCO - Life Technologies 
(Grand Island, USA) 
Fetal Calf Serum 
(FCS) 
A10108-
2367 
A15-101 PAA (Pasching, Austria) 
Sodium-pyruvate 
(100 mM) 
749750 11360 GIBCO - Life Technologies 
Non-essential amino 
acids (100x) 
930229 11140 GIBCO - Life Technologies 
Penicillin / 
Streptomycin 
(5 g/ml) 
918582 15070 GIBCO - Life Technologies 
-Mercaptoethanol 
(50 mM) 
806672 31350 GIBCO - Life Technologies 
 
3.2.2. Medium for cell culture 
T cells and thymocytes were cultured in RPMI 1640, supplemented with 10% FCS, 1 
mM Sodium-pyruvate, 1x non-essential amino acids, 50 g/ml Penicilline/Streptomycin 
and 50 M -Mercaptoethanol. 
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3.2.3. Reagents, antibodies and cytokines used for cell stimulation 
Reagent Lot. # Order # Company 
Anti-murine CD3 
(Clone 145-2C11) 
B133074 100314 Biolegend 
(San Diego, USA) 
Phorbol 12-myristate 
13-acetate (PMA) 
16561-29-8 P8139 Sigma Aldrich 
Ionomycin 56092-82-1 I-0634 Sigma Aldrich 
Murine interleukin-2 MX1210031 402-ML 
R&D Systems 
(Minneapolis, USA) 
CD95L 
(scErbB2) 
- - 
Self-produced 
(HEK293 cells) 
TRAIL 810904 - 
Novitec 
(Freiburg im Breisgau, 
Germany) 
TNF - 410-MT-010 R&D (Minneapolis, USA) 
FasFc - - 
Self-purified - FPLC 
(HEK293 cells) 
Q-VD-OPh OPH109 03OPH10901 
MP Biomedicals 
(Aurora, OH, USA) 
Dexamethasone - 
D4902-
100mg 
Sigma Aldrich 
 
 
3.3. Materials, devices and reagents for flow cytometry 
3.3.1. Devices 
Labelled samples were analyzed on BD LSRFortessa and BD LSR II by Becton 
Dickinson (New Jersey, USA). Cell purification was performed using FACS Aria II 
(Becton Dickinson) or Moflo (Beckman Coulter, Indianapolis, USA) devices. 
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3.3.2. Fluorescent dyes 
Reagent Excitation Emission Company 
LIVE/DEAD® 
Blue fluorescent reactive 
dye 
350 nm 450 nm Life Technologies 
Tetramethylrhodamine 
ethyl ester (TMRE) 
549 nm 574 nm Enzo Life Sciences 
7-amino-actinomycin D 
(7AAD) 
543 nm 647 nm BD Biosciences 
Annexin V-APC 650 nm 660 nm Becton, Dickinson 
 
3.3.3. Flow cytometry antibodies 
Reactivity Fluorochrome Species/Isotype Clone Order # Company 
humanCD2 APC 
Mouse 
IgG1, 
RPA-
2.10 
300214 Biolegend 
CD4 PacificBlue Rat IgG2A, RM4-5 100531 Biolegend 
CD8 PE-Cy7 Rat IgG2A, 53-6.7 100722 Biolegend 
CD25 APC Rat IgG2A, PC61.5 17-0251 Biolegend 
CD44 APC Rat IgG2A, IM7 103012 Biolegend 
CD62L PerCP/Cy5.5 Rat IgG2A, MEL-14 
45-0621-
82 
eBioscience 
Ki67 PE 
Mouse 
IgG1, 
B56 556027 
Becton, 
Dickinson 
Foxp3 
AlexaFluor 
488 
Rat IgG2A, FJK-16s 
53-5773-
82 
eBioscience 
Foxp3 PE Rat IgG2A, FJK-16s 
12-5773-
80 
eBioscience 
CD95 PE 
Armenian 
Hamster IgG 
MFL3 106605 Biolegend 
CD262 
(DR5) 
PE 
Armenian 
Hamster IgG 
MD5-1 119905 Biolegend 
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Reactivity Fluorochrome Species/Isotype Clone Order # Company 
TNFR1 PE 
Armenian 
Hamster IgG 
55R-286 113003 Biolegend 
Isotype 
control 
PE 
Armenian 
Hamster IgG 
Ha4/8 553965 
BD 
Pharmingen 
CD16/CD32 
(FcBlock) 
- Rat IgG2B,  2.4G2 553142 BD 
*Antibodies have mouse reactivity, if not stated otherwise. 
 
3.4. Reagents and materials used for Western blotting 
PVDF membrane and photosensitive Hyperfilms® were purchased from GE Healthcare 
(Buckinghamshire, UK). Blotting and transfer devices from Bio-Rad Laboratories 
(Hercules, USA) were used for SDS-PAGE and protein transfers. 
3.4.1. Primary antibodies  
Antibody Reactivity Isotype Species Clone Company 
Anti--
Actin 
Mouse, 
Human 
IgG2A Mouse AC-74 Sigma-Aldrich 
Anti-
Cleaved 
Caspase 3 
Mouse, 
Human, Rat, 
Monkey 
IgG Rabbit  
Cell Signaling 
(Massachusetts, 
USA) 
Anti-Foxp3 
Mouse, 
Human 
IgG1 Mouse eBio7979 eBioscience 
 
3.4.2. Horseradish peroxidase-conjugated secondary antibodies 
Reactivity Species Clone Company 
Mouse IgG1 Goat 1070-09 
Southern Biotechnology 
(Birmingham, USA) 
Mouse IgG2a Goat 1080-05 Southern Biotechnology 
Rabbit IgG Goat 5030-05 Southern Biotechnology 
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3.5. Reagents and devices for confocal microscopy 
Fluorescent microscopic pictures were taken with a Nikon Eclipse Ti (Düsseldorf, 
Germany) microscope, equipped with an UltraViewVox Spining Disc module by Perkin 
Elmer (Waltham, USA) 
3.5.1. Reagents for microscopy 
3.5.1.1. Fluorescent dyes 
Reagent Excitation Emission Order # Company 
CellEvent® 
Caspase-3/7 Green 
Detection Reagent 
503 nm 530 nm C10423 Life Technologies 
 
3.5.1.2. Fluorochrome-labeled antibodies 
Reactivity Fluorochrome Species Clone Order # Company 
humanCD2 APC 
Mouse 
IgG1, 
RPA-
2.10 
300214 Biolegend 
CD4 PacificBlue Rat IgG2A, RM4-5 100531 Biolegend 
 
 
3.6. Reagents for in vivo treatments 
Reagent Clone Order # Company 
Anti-murine CD95L MFL3 106608 Biolegend 
Anti-murine CD95L 3C82 *  
Q-VD-OPh - 
SML0063-
5MG 
Sigma Aldrich 
*This antibody was a kind gift of Prof. Dr. Klaus Schultze-Ostoff from Universität 
Tübingen. 
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3.7. Frequently used buffers 
Group Buffer Components 
Cellular buffers PBS 
138 mM NaCl, 8.1 mM NA2HPO4,  2.7 
mM KCl, 1.5 mM K2HPO4, pH7.4 
 FACS Buffer 2% w/v BSA in PBS 
 
10x Annexin V binding 
buffer 
0.1 mM HEPES / NaOH, 1.4M NaCl, 
25 mM CaCl2, pH 7.4 
Lysis buffers TPNE 
1% v/v Triton X-100, 2 mM EDTA, in 
PBS ad 300 NaCl mM, pH 7.4 
 100x protease inhibitors 
100 μg/ml Apotinin, 100 μg/ml 
Leupeptin, 100 μg/ml Chymostatin, 
100 μg/ml Pepstatin 
Western blot 
buffers 
5x Laemmli 
50 mM Tris, pH 6.8, 10% w/v SDS, 
25% v/v -Mercaptoethanol, 50% v/v 
Glycerol, 0.25 mg/ml Bromphenolblue 
 Running buffer 
25 mM Tris, pH 8.0, 192 mM Glycerin, 
1% v/v SDS 
 Transfer buffer 
25 mM Tris, pH 8.0, 192 mM Glycerin, 
20% v/v Methanol 
 Blocking buffer 
5% w/v non-fat dry milk, 0.2 % v/v 
Tween-20 in PBS 
 TBS 
137 mM NaCl, 2.68 mM KCl, 
24.76 mM Tris, pH 7.4 
 Washing buffer 0.05% v/v Tween-20 in TBS 
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3.8. Oligonucleotides 
HPLC-purified oligonucleotides were supplied by Eurofins MWG Operon (Ebersberg, 
Germany). 
3.8.1. Oligonucleotides for quantitative RT-PCR 
Name Sequence (5’3’) 
UBC fwd AAGAGAATCCACAAGGAATTGAATG 
UBC rev CAACAGGACCTGCTGAACACTG 
cFLIP fwd ACCCTCACCTGGTTTCTGATT 
cFLIP rev TCGTTCTGATCTAAGCTCTCACC 
cFLIPL fwd GCAGAAGCUCUCCCAGCA 
cFLIPL rev UUUGUCCAUGAGUUCAACGUG 
cFLIPR fwd UCCAGAAGUACACCCAGUCCA 
cFLIPR rev CACUGGCUCCAGACUCACC 
 
3.8.2. Oligonucleotides for mouse genotyping 
Name Sequence (5’3’) 
Foxp3 WT fwd CCTAGCCCCTAGTTCCAACC 
Foxp3 WT rev AAGGTTCCAGTGCTGTTGCT 
Foxp3 Mut fwd AGGATGTGAGGGACTACCTCCTGTA 
Foxp3 Mut rev TCCTTCACTCTGATTCTGGCAATTT 
FLIP flox fwd CATGAGCACTGAGGGACACA 
FLIP flox rev GCGGAGTTTGCTACAGGAAG 
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3.9. Mouse strains 
Foxp3
tm1(CD2/CD52)Shori
 mice
205
, referred to as Foxp3-hCD2 and C57BL/6-Tg(Foxp3-
GFP)90Pkraj/J mice
206
, referred to as Foxp3-GFP were used as Treg reporter mice. 
B6.129(Cg)-Foxp3
tm4(YFP/cre)Ayr
/J mice, referred to as Foxp3
Cre
, were previously 
described
207
. B6.129-Cflar
tm1Ywh
/J mice, referred to as Cflar
fl
, were previously 
described
136
. The two previous mouse strains were used to generate the Cflar
Foxp3
 
mouse strain. If not stated otherwise, experiments were performed using littermate 
controls animals. The mice were kept under specific pathogen free conditions in the 
animal facility of the Helmholtz Centre for Infection Research, Braunschweig, 
Germany. All breeding and experiments were performed in accordance with the 
guidelines of national and local authorities. 
 
 
4. Experimental procedures 
4.1. Molecular biology methods 
4.1.1. RNA isolation 
Cell lysis was performed by means of QIAshredder columns from Qiagen (Hilden, 
Germany). RNA of eukaryotic cells was purified using RNeasy Kit from Qiagen. Both 
procedures were done according to manufacturer’s instructions. 
4.1.2. Photometric determination of DNA/RNA concentration 
DNA/RNA concentrations were determined by means of a Nanodrop 2000c (Thermo 
Scientific). Lambert-Beer function was used for calculations. 
c =  x d x E-1 
c = concentration (mol/l) 
 = coefficient of extinction (M-1 x cm-1) 
d = density of the cuvette (cm) 
E = extinction 
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4.1.3. Reverse transcription 
100 ng of purified RNA were used as template to generate a complementary DNA 
(cDNA) strand by means of Revert
TM
 Premium First Strand cDNA Synthesis Kit 
(Thermo Scientific). Oligo(dt)18 primers were used for the RNA transcription according 
to supplier’s protocol. Incubations were done in peqSTAR thermocycler from PEQLAB 
(Erlangen, Germany). 
 
4.1.4. Polymerase chain reaction (PCR) 
DNA obtained from mouse tissue by means of KAPA Express Extract (PEQLAB), was 
used for mouse genotyping. DNA amplification was performed using 2x KAPA Fast 
ReadyMix (PEQLAB) according to the following pattern: 
Component Amount 
DNA template 1 l (50-100 ng) 
2x Ready-to-use mix 12.5 l 
Forward primer 1 l (100 pmol) 
Reverse primer 1 l (100 pmol) 
H2O 9.5 l 
 
 
PeqSTAR thermocycler (PEQLAB) was used for incubation according to the following 
program: 
Time Temperature Function Cycles # 
5 minutes 94 ºC Initial denaturation 1 
30 seconds 94 ºC Denaturation  
30 seconds 60º C (+/- x)* Hybridization 25-32 
30 seconds 72º C Elongation  
10 minutes 72º C Terminal elongation 1 
     *Hybridization temperature was chosen 3º C under the TM of the respective primer combination 
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4.1.5. Analytic agarose gels 
1-2% agarose gels were used to separate DNA fragments, according to their length, by 
means of an electric field of 150 mA in the horizontal gel-electrophoresis system 
perfectBlue M (PEQLAB) in TAE buffer (40 mM Tris pH 8, 20 mM acetic acid, 1 mM 
EDTA) with 0.5 g/ml ethidiumbromide. 1kB DNA ladder by PEQLAB was used as 
standard. The ethidiumbromide-DNA was visualized by UV-light ( = 254nm). 
 
4.1.6. Quantitative real-time polymerase chain reaction (qRT-PCR) 
cDNA obtained from RNA of eukaryotic cells (see 4.1.1., 4.1.2. and 4.1.3.) was used 
for amplification in order to determine gene expression by means of qPCR analysis. 
SYBR Green I Master, 2x concentrated by Roche (Mannheim, Germany) was used to 
detect double strand DNA during qPCR amplification in a LightCycler® 96 System 
device from Roche. Gene expression was determined by relative quantification using 
Ubiquitin-conjugating enzyme E2D 2A  (UBC) as reference gene. DNA Amplification 
and fluorescence measurement was done using the following program: 
Time Temperature Function Cycles # 
1 minute 95 ºC Preincubation 1 
10 seconds 95 ºC Single   
10 seconds 60º C  Mode of 45 
10 seconds 72º C Acquisition  
10 seconds 95º C Continuous  
60 seconds 65º C Mode of 1 
1 second 97º C Acquisition  
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4.2. Protein biochemical methods 
4.2.1. Cell lysis 
TPNE lysis buffer supplemented with leupeptin, aprotinin, chymostatin and pepstatin A 
was used to get whole cell extracts. Cells were incubated on ice for 20 minutes and 
centrifuged (20.000g) for 15 minutes. After the incubation, supernatant was transfer to a 
prechilled tube. 
4.2.2. Determination of protein concentration 
Bicinchoninic acid (BCA) assay, provided by Pierce – Thermo Fisher Scientific, was 
used to determine total protein amount of lysates generated as indicated in 4.2.1. 
according to supplier’s instructions. Absorption was as measured at 562 nm determined 
in a TECAN infinite 200M device (Männedorf, Switzerland). 
4.2.3. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
20 g of protein lysate was mixed with 5x Laemmli buffer to a 1x final concentration 
and incubated at 95º C for 5 minutes. Biorad “Tetra cell” was used to separate the 
proteins in a 12% polyacrylamide gel at 33mA and 80V. 
4.2.4. Western blotting 
Biorad “Criterion Blotter” was used to transfer the proteins from SDS-PAGE to a PVDF 
membrane (GE healthcare) in 1x Transfer buffer at 500 mA at 80 V for 90 minutes. 
Afterwards, the membrane was incubated in blocking buffer for 1 hour at room 
temperature (RT) with constant agitation. Subsequently, the membrane was transferred 
into blocking buffer solution containing the primary antibody, diluted according to 
supplier’s instructions, and incubated overnight. After the incubation, the membrane 
was washed 3 times with washing buffer and incubated with the secondary antibody for 
one hour at RT with agitation. Afterwards the membrane was washed 3 times with 
washing buffer and proteins were detected using SuperSignal West Dura substrate from 
Pierce - Thermo Fisher Scientific. 
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4.3. Mouse surgery and cellular methods 
4.3.1. Isolation of mouse organs 
Mice were sacrificed by cervical dislocation or CO2. Thymus, spleen and peripheral 
lymph nodes were isolated from mice. Peripheral lymph nodes included cervical, 
axillar, brachial and inguinal lymph nodes. Lymphoid organs were milled through a 45 
m filter. Resulting cells were resuspended in PBS.  
4.3.2. Flow cytometry analysis 
For ex vivo analysis, 1x10
6
 cells were washed twice with PBS, resuspended in 100 l 
PBS and stained with LIVE/DEAD® Blue fluorescent reactive dye, diluted according to 
manufacturer’s protocol. After 30 minutes incubation at 4º C in the dark, cells were 
washed twice with PBS, resuspended in FACS buffer containing FcBlock antibodies 
and incubated for 15 minutes at 4ºC in the dark. Subsequently, cells were washed twice 
with FACS buffer, resuspended in 100 l of FACS buffer and stained with the 
respective surface antibodies. After incubation for 15 minutes at 4ºC in the dark, cells 
were washed twice with FACS buffer. In the case of intracellular marker 
determinations, cells’ fixation and permeabilization was performed using FoxP3 
Staining Buffer Set by Miltenyi Biotec (Mönchengladbach, Germany) following 
supplier’s instructions. 
For studies of viability/apoptosis determined by flow cytometry, cells were firstly 
stained with the respective surface markers according to the indications mentioned 
above. Next, TMRE or Annexin V/7AAD staining was performed for cell viability 
determination. For TMRE staining, cells were resuspended in 250 l of FACS buffer, 
stained with TMRE and incubated for 20 minutes at RT in the dark. Then, 250 l of 
FACS buffer was added to stop the staining and samples were analyzed by flow 
cytometry. For Annexin V/7AAD staining, cells were resuspended in 250 l of 1x 
Annexin V binding buffer containing 3 l of Annexin V and 1.5 l of 7AAD, and 
incubated for 20 minutes at RT in the dark. After the incubation, 250 l of 1x Annexin 
V binding buffer was added to stop the staining and samples were analyzed by flow 
cytometry. 
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4.3.3. Cell isolation by flow cytometry 
Primary cells were stained with the respective surface markers as mentioned in 4.3.2. 
and were sorted by means of a FACS Aria II or Moflo device and collected in tubes 
containing PBS. This procedure was performed in cooperation with Dr. Lothar Gröbe, 
head of the flow cytometry and cell sorting facility at the Helmholtz Center for Infection 
Research (Braunschweig, Germany). 
4.3.4. Viability studies in Tcon and Treg cells 
Tcon and Treg cells were sorted from lymph nodes and spleen of Foxp3-GFP reporter 
mice. The cells were seeded in primary T cell medium (see 3.2.2.) and incubated for 
different time points (0, 24, 48, 72 hours) in the absence or presence of coated anti-CD3 
(10 g/ml), IL-2 (50 ng/ml), QVD (10 M) and dexamethasone (0.5 M). After 
incubation, cells were harvested, stained with Annexin V/7AAD and analyzed by flow 
cytometry. 
4.3.5. Active caspase 3 detection by Western blot 
Tcon and Treg cells were sorted from lymph nodes and spleen of Foxp3-GFP reporter 
mice. The cells were seeded in primary T cell medium (see 3.2.2.) and incubated for 2 
hours in the absence or presence of PMA (10 ng/ml), ionomycin (1 µM), and anti-IL 2 
(50 ng/ml). Then, the cells were harvested and protein lysates were obtained for 
Western blotting analysis. 
4.3.6. In vitro stimulation with death ligands 
Sorted Tcon and Treg from Foxp3-GFP mice cells were stimulated with 20 ng/ml 
CD95L, 20 ng/ml TRAIL, 20 ng/ml TNF (R&D) or 0.5 M dexamethasone for 16 
hours. A FasFc fusion protein (50 g/ml) was used to block CD95L-induced cell death. 
Primary cells from the thymus of Cflar
Foxp3 
and control mice were incubated for 16 
hours with 200 ng/ml CD95L, 20 ng/ml TRAIL, 20 ng/ml TNF and 0.5 M 
dexamethasone, respectively. After incubation, cells were harvested, stained with 
Annexin V/7AAD and analyzed by flow cytometry. 
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4.3.7. Active caspase 3/7 determination by confocal microscopy 
Primary cells from lymph nodes stained with anti-CD4-PacificBlue and hCD2-APC 
antibodies as in 4.3.2. Subsequently, cells were washed with PBS, resuspended in 1ml 
PBS and incubated with 50 l of CellEvent® Caspase-3/7 Green Detection Reagent for 
10 minutes at RT in the dark. Finally, samples were transferred to an 8-well cell culture 
chamber (Sarstedt, Germany) and analyzed by confocal microscopy.  
Tcon and Treg cells were purified from Foxp3-hCD2 mice and stimulated with death 
ligands as in 4.3.6. for 16 hours. After incubation, both cell types were stained with 
CellEvent® Caspase-3/7 Green Detection Reagent as mentioned above and analyzed by 
confocal microscopy. 
 
4.3.8. Histology and immunohistochemistry  
Cflar
Foxp3 
and control mice were sacrificed and lung, skin, pancreas and spleen tissue 
was isolated. Samples were fixed with 4% formaldehyde and embedded in paraffin. 3 
m sections were cut, deparaffinized and stained with hematoxilin and eosin for 
histological analysis. Furhermore, thymus, spleen and lymph node sections were stained 
with Foxp3 antibody. Histological analysis and immunohistochemistry determinations 
were done in cooperation with Dr. Marina Pils, head of the mousepathology facility at 
the Helmholtz Center for Infection Research (Braunschweig, Germany).  
 
4.3.9. Determination of cytokines in serum 
Blood was obtained by means of the final heath puncture method. Samples were 
incubated at 37ºC for 1 hour, then 10 minutes at 4ºC and finally centrifuged.  The 
supernatant was transferred to another tube and stored at -80ºC. Cytokine levels from 
serum were determined using Th1/Th2 Mouse 6-Plex Panel (LifeTechnologies) in a 
Luminex® Instrument of the Luminex Corporation (Austin, USA) following supplier’s 
protocol. 
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4.3.10. Autoantibodies determination 
20 g of liver and kidney extracts from RAG2-deficient mice were loaded onto a 12 % 
SDS-polyacrylamid gel and a Western blot analysis was implemented. PVDF 
membrane was incubated with serum diluted to a protein concentration of 5 g/ml from 
Cflar
Foxp3 
and control mice for autoantibody detection in the respective serum. 
4.3.11. In vivo treatments 
Cflar
Foxp3 
and control mice were treated with 100 g of anti-CD95L via intraperitoneal 
injection at days 7, 9 and 11 after birth. Mice were sacrificed at day 12 after birth for 
lymphoid organ isolation and flow cytometry analysis. 
Cflar
Foxp3 
and control mice were treated with 100 g of QVD via intraperitoneal 
injection at days 8, 9 and 10 after birth. Mice were sacrificed at day 11 after birth for 
lymphoid organ isolation and flow cytometry analysis. 
 
4.4. Statistical Analysis  
Statistical analyses were performed by Mann-Whitney-tests to determine statistical 
significance, using Graph Pad Prism (Graph-Pad-Software Inc., La Jolla, CA, USA). 
Standard error of the mean (SEM) were represented as error bars in the graphs. 
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5. Results 
5.1 Regulatory T cells manifest a higher apoptosis rate than conventional T cells 
Treg cells are considered as a very dynamic population with a high turnover. Some 
studies support this idea showing a high basal proliferation rate in this T cell 
subset
195,199
. Hence, a compensatory mechanism is needed in order to maintain the size 
of the population. It would seem logical to think that Treg cells have also a high cell 
death rate to compensate the high proliferation rate. However, to date, only few studies 
have been performed corroborating that fact
199,208,209
. Thus, the analysis of the apoptosis 
rate in Treg cells is a pertinent study in order to corroborate previous findings, which 
indicated that Treg cells are a dynamic population. One consequence of apoptosis is the 
mitochondrial permeabilization leading to the loss of mitochondrial membrane potential 
(MMP)
210
. It is possible to take advantage of this fact in order to measure cell apoptosis 
using tetramethylrhodamine ethyl ester (TMRE). Since TMRE is permeable to the 
mitochondrial membrane and a positively-charged red dye, it can be incorporated by 
active mitochondria. Thus, depolarized mitochondria, having decreased membrane 
potential, are less efficient in the incorporation of TMRE and therefore they show 
reduced staining. Ex vivo Treg and conventional T (Tcon) cells from thymus, spleen, 
peripheral lymph nodes (pLN) and mesenteric lymph nodes (mLN) of Foxp3-GFP mice 
were stained with TMRE and analyzed by flow cytometry. Since TMRE staining is not 
compatible with cell fixation, the cells were obtained from Foxp3-GFP mice, which 
express green fluorescent protein (GFP) in Foxp3-expressing cells, allowing 
discrimination between Foxp3 positive and negative cells. The TMRElow subpopulations 
were significantly higher in Tregs compared to Tcon cells, indicating increased 
mitochondrial depolarization and suggesting higher apoptosis in the Treg population 
(Figure 13). 
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Figure 13. Treg cells have higher frequencies of TMRElow than Tcon cells 
(A) Representative histograms of TMRE stainings of thymus, spleen, pLN and mLN of Foxp3-
GFP. (B) Bar graph of the percentages of TMRElow subpopulations within Tcon and Treg cells 
(n=20 for thymus and spleen; n=19 for pLN and mLN). Bar graphs represent the mean; error 
bars represent SEM. Statistical analyses were performed by two-tailed Mann-Whitney tests; 
**p<0.01. 
 
Since changes in the mitochondrial membrane potential are not an exclusive process of 
T cell apoptosis
211
, alternative methods were used to assess the apoptosis rate in Tcon 
and Treg cells. During the apoptotic cell demolition, phosphatidylserine (PS) molecules, 
which are normally in the inner layer of the plasma membrane, are exposed on the cell 
surface. It is possible to detect exposed PS molecules on cells using the protein Annexin 
V, which binds specifically to PS
16
, coupled with a fluorochrome. Moreover, the 
combination of Annexin V and a fluorescent DNA intercalator dye, like and 7-
aminoactinomycin D (7AAD), allows discrimination between live cells, early apoptotic 
cells, which are only stained with Annexin V, and late apoptotic/necrotic cells, which 
are double positive for 7AAD and Annexin V by flow cytometry. In line with the 
previous results, higher frequencies of apoptotic cells, detected by their PS exposure, 
were found within the Treg population compared to Tcon cells in thymus, spleen, pLN 
and mLN of Foxp3-GFP mice (Figure 14). 
 
 
 
 
A B 
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Figure 14. Annexin V (AxV) frequencies are higher in Treg than in Tcon cells. 
(A) Representative dot plots of AnnexinV/7AAD staining of Tcon and Treg cells from thymus, 
spleen, peripheral and mesenteric lymph nodes of Foxp3-GFP mice (n=12 for tymus, spleen and 
pLN; n=11 for mLN). AxV
-
/7AAD
-
 cells are living cells, AxV
+
/7AAD
-
 are early apoptotic cells, 
and AxV
+
/7AAD
+
 are late apoptotic/necrotic cells. (B) Bar graph summary of AxV
+
/7AAD
-
 
(early apoptotic) cells of Tcon and Treg cells from thymus, spleen, pLN and mLN of Foxp3-
GFP mice. Bar graphs represent the mean; error bars represent SEM. Statistical analyses were 
performed by two-tailed Mann-Whitney tests; *p< 0.05. 
 
 
A characteristic feature of apoptosis is the activation of caspase, such as the effector 
caspases 3 and 7
13
. The presence of active caspase 3/7 was tested in Tcon and Treg cells 
from lymph nodes of Foxp3-hCD2 reporter mice, using a fluorogenic substrate, which 
is processed by the active form of caspase 3 and 7 and stains the cell nucleus. Human 
CD2 (hCD2) expression on the cell surface correlated with Foxp3 expression, allowing 
the detection of Treg cells with a surface reporter marker. Consistently with the 
previous results, higher frequency of active caspase positive events was found by 
confocal microscopy in Treg compared to Tcon cells (Figure 15). 
 
Figure 15. Active caspase 3/7 frequencies are higher in Treg than in Tcon cells. 
(A) Representative confocal images of CD4, hCD2 (Foxp3) and active caspase 3/7 staining. 
Scale bars= 19 m. (B) Summary graph of frequencies of active caspase 3/7 in Tcon and Treg 
cells (n=5). Bar graphs represent the mean; error bars represent SEM. Statistical analyses were 
performed by two-tailed Mann-Whitney tests; *p< 0.05 
A B 
A B 
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Taken together, the results of the mitochondrial depolarization (TMRE defective 
uptake), plasma membrane disorganization (Annexin V exposure), and caspase 
activation, indicate higher apoptosis rate in Treg cell compared to Tcon cells, 
determined by ex vivo analysis. 
 
5.2 Pan-caspase inhibitor and IL-2 improves Treg viability 
After providing evidence that the cell death rate is higher in Treg cells compared to 
Tcon cells, an apoptotic inhibitor was used in order to determine whether apoptosis 
participates in Treg cell death. For this purpose, Treg cells were purified from Foxp3-
GPF mice by sorting and cultivated in the absence and presence of IL-2, Q-VD-OPh 
(QVD) or dexamethasone for different time points (24, 48 and 72 hours). IL-2 was 
previously described as an important pro-survival factor for Treg cells. This cytokine, 
through the activity of anti-apoptotic proteins, blocks the mitochondrial 
permeabilization and the initiation of the intrinsic pathway of apoptosis
198
. On the other 
hand, QVD is a pan-caspase inhibitor, and therefore prevents cell apoptosis
212
. Finally, 
the synthetic glucocorticoid dexamethasone was used as positive control because of its 
known potent apoptotic activity in T cells
213,214
 . Cell viability was assessed using 
Annexin V-7AAD staining by flow cytometry. IL-2 as well as QVD treatment increased 
Treg cell viability compared to untreated cells. Remarkably, QVD was more efficient 
blocking apoptosis than IL-2 treatment. As expected, dexamethasone treatment induced 
efficiently massive cell death in the cell cultures. All these data corroborate the key role 
of apoptosis in Treg cell death (Figure 16). 
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Figure 16. In vitro Treg viability improved upon QVD and IL-2 stimulation. 
(A) Representative dot plots and (B) kinetics of Treg cell viability determined by 
AnnexinV/7AAD staining. Cells were purified from GFP-Foxp3 reporter mice by FACS 
sorting. They were cultivated without stimulation and in the presence of IL-2, QVD, and 
dexamethasone (DEX). AxV
-
/7AAD
-
 cells are viable cells (n=6). Each point represents the 
mean and error bars represent SEM. Statistical analyses comparing untreated vs. QVD samples 
were performed by one-tailed Mann-Whitney tests; *p< 0.05. 
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Furthermore, sorted Treg cells were also stimulated with anti-CD3 in order to induce 
cell death. T cell receptor (TCR) stimulation, in the absence of co-stimulatory signals, 
promotes apoptosis
143,215
. However, TCR stimulation together with co-stimulatory 
CD28-derived signals, which regulates the anti-apoptotic protein BCL-XL, promotes 
cell activation instead of cell death
216–218
. For this purpose, anti-CD3 coated plates were 
used to cultivate the cells. Comparable to the previous data, IL-2 could improve Treg 
viability whereas QVD was even more efficient than IL-2 blocking apoptosis. Like in 
the previous experiment, dexamethasone killed massively activated Treg cells (Figure 
17). 
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Figure 17.  Viability of anti-CD3-stimulated Treg cells improved by QVD and IL-2 in vitro 
stimulation. 
(A) Representative dot plots and (B) kinetics of Treg cell viability determined by 
AnnexinV/7AAD staining. Cells were purified from GFP-Foxp3 reporter mice by FACS 
sorting. They were cultivated in anti-CD3 coated plates in absence and presence of IL-2, QVD, 
and dexamethasone (DEX). AxV
-
/7AAD
-
 cells are viable cells (n=6). Each point represents the 
mean and error bars represent SEM. Statistical analyses comparing untreated vs. QVD samples 
were performed by one-tailed Mann-Whitney tests; *p< 0.05, **p<0.01; n.s., not significant. 
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Parallel to the Treg cell cultures, sorted Tcon cells were cultivated also in the presence 
of IL-2, QVD and dexamethasone. Unlike the Treg cells, the viability of the Tcon cells 
was not affected by either IL-2 or QVD stimulation (Figure 18).  
 
 
Figure 18. In vitro Tcon viability did not improve upon QVD and IL-2 stimulation. 
(A) Representative dot plots and (B) kinetics of Tcon cell viability determined by 
AnnexinV/7AAD staining. Cells were purified from GFP-Foxp3 reporter mice by FACS 
sorting. They were cultivated without TCR triggering and in the presence of IL-2, QVD, and 
dexamethasone (DEX). AxV
-
/7AAD
-
 cells are viable cells (n=6). Each point represents the 
mean and error bars represent SEM. Statistical analyses comparing untreated vs. QVD samples 
were performed by one-tailed Mann-Whitney tests; n.s., not significant. 
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When the Tcon cells were cultivated in anti-CD3 coated plates and stimulated with IL-2 
and QVD, the viability of Tcon cells improved by QVD treatment. In contrast, IL-2 did 
not improve the Tcon cell viability (Figure 19).   
 
 
 
Figure 19.  Viability of anti-CD3-stimulated Tcon cells improved upon QVD but not IL-2 
in vitro stimulation. 
(A) Representative dot plots and (B) kinetics of Tcon cell viability determined by 
AnnexinV/7AAD staining. Cells were purified from GFP-Foxp3 reporter mice by FACS 
sorting. They were cultivated in anti-CD3 coated plates in absence and presence of IL-2, QVD, 
and dexamethasone (DEX). AxV
-
/7AAD
-
 cells are viable cells (n=6). Each point represents the 
mean and error bars represent SEM. Statistical analyses comparing untreated vs. QVD samples 
were performed by one-tailed Mann-Whitney tests; *p< 0.05; n.s., not significant. 
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All these data together indicate that Treg cells, contrary to Tcon cells, were prone to die 
and they needed anti-apoptotic stimuli to remain viable. Moreover, Tcon cells became 
sensitive to apoptosis, like Treg cells, upon activation stimuli. On the other hand, the 
viability of Tcon and Treg cells at time point 0 hours was remarkable low. This fact was 
due to the inflation of necrotic cells, detected as AxV
+
/7AAD
+
, caused by the cell 
sorting and sample preparation. Most of the necrotic cells in the further time points are 
probably degraded and therefore out of the detection limit set for the flow cytometric 
analysis. 
In addition, Treg cells sorted from Foxp3-GFP mice and cultured for two hours, showed 
the active form of caspase-3 in contrast to Tcon cells. Phorbol 12-myristate 13-acetate 
(PMA), through protein kinase C activation, and ionomycin, which raises the 
intracellular levels of calcium, mimic TCR-CD28 T lymphocyte activation. 
Remarkably, the activation of caspase-3 in the Treg cells was reverted upon IL-2, PMA 
and ionomycin stimulation during two hours (Figure 20).  
 
 
 
Figure 20. PMA, ionomycin and IL-2 stimulation repressed spontaneous caspase 3 
activation in Treg cells after 2 hours in culture. 
Immunoblot analysis of active caspase-3 presence in Tcon and Treg cells after 2 hours of 
culture in the presence or absence of IL-2, phorbol myristate acetate (PMA) and ionomycin. 
Cells were purified from Foxp3-GFP reporter mice using FACS sorting. 
 
5.3 cFLIP deficiency in Treg cells caused autoimmune disease in mice 
Once confirming that cell death was prominent in Treg cells and is mainly caused by 
apoptosis, the next question was how this mechanism is mediated. Studies published in 
the last years implicated the intrinsic pathway in the regulation of the Treg 
apoptosis
198,199,208
. However, nothing is known so far about the possible contribution of 
the death receptor-mediated pathway to the Treg homeostasis. The usage of the Cre-Lox 
system allows deleting target genomic sequences flanked by Lox sequences by 
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recombination
219
. To study the impact of the extrinsic pathway on Treg cell death, the 
inhibitor of the extrinsic pathway c-FLIP was deleted specifically in Treg cells. To this 
end, a mouse line was generated crossing mice expressing the recombinase enzyme Cre 
under the control of the Foxp3 promotor with mice containing loxP sites surrounding 
Cflar, the gene encoding cFLIP. Cflar
fl/wt 
- Foxp3
Cre/wt 
female mice and Cflar
fl/wt 
-
Foxp3
Cre/Y
 male mice were used to generate the deletion of Cflar in regulatory T cell. 
Multiple genotype combinations resulted from the crossing of these mice, however only 
Cflar
fl/fl 
- Foxp3
Cre/Cre 
females
 
and
 
Cflar
fl/fl 
- Foxp3
Cre/Y 
males, hereafter referred to as 
Cflar
Foxp3
,
 
showed a different phenotype compared to the rest of the resulting 
genotypes, which were later grouped and considered as control mice (Figure 21).  
 
 
Figure 21. Breeding strategy and resulting genotypes to generate Cflar
Foxp3 
mice 
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A consequence of the deletion of cFLIP in the Treg cells of Cflar
Foxp3 
mice was that the 
Treg cells were barely detectable in the periphery (spleen and lymph nodes). 
Remarkably, thymic Treg production was not impaired in the Cflar
Foxp3 
(Figure 22). 
 
 
Figure 22. Treg cells were present in the thymus of Cflar
Foxp3
 mice but absent in the 
spleen and lymph nodes. 
Representative Foxp3 immunostaining of thymus, spleen and peripheral lymph nodes sections 
of 2 weeks old Cflar
Foxp3
 mouse and littermate control. 
 
Confirming the results of the histological analysis, Treg cell frequencies, measured by 
flow cytometry, were extremely low in spleen and lymph nodes of Cflar
Foxp3 
mice 
(Figure 23A and 23B). Again Treg cells in the thymus showed comparable frequencies 
to the controls (Figure 23A and 23B). Treg cell absolute numbers followed similar 
differences in the spleen and lymph nodes, being always much lower in the Cflar
Foxp3 
mice (Figure 23C). Nevertheless, although the Treg cell frequencies in the thymus were 
comparable in Cflar
Foxp3 
and control mice, the absolute numbers in the thymus were 
substantially lower in Cflar
Foxp3 
mice due to reduced organ size in these mice (Figure 
23). 
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Figure 23. Treg cells showed normal frequencies in thymus but were barely detectable in 
the periphery of Cflar
Foxp3
. 
(A) Representative flow cytometric dot plots, (B) percentages and (C) absolute numbers of 
Foxp3
+
 Treg cells within the CD4
+
 CD8
-
 population from thymus, spleen and peripheral lymph 
nodes of 2-3 weeks old Cflar
Foxp3 
mice and littermate control mice are shown (n=7 each; except 
thymus Cflar
Foxp3 
which is n=4). Bar graphs represent the mean; error bars represent SEM. 
Statistical analyses were performed by two-tailed Mann-Whitney tests; *p< 0.05, **p<0.01. 
 
In the case of females, the genotype Cflar
fl/fl 
- Foxp3
Cre/wt
 was included within the 
control mice, since they showed comparable phenotype to the other genotypes included 
in the control group. Despite containing loxP sites in both Cflar alleles and one X 
chromosome containing the Cre recombinase, they did not develop abnormalities like 
the Cflar
Foxp3
 genotypes.  
In order to check the effect of the random X chromosome inactivation in female mice, 
Cre-YFP expression, within the Treg compartment of Cflar
fl/fl
-Foxp3
Cre/wt
, Cflar
fl/WT
-
Foxp3
Cre/wt
 and Cflar
wt/wt
-Foxp3
Cre/wt
, was analyzed by flow cytometry. Since YFP 
fluorescence is affected by the cell fixation/permeabilization during the staining 
process, the CD25 cell surface marker was used to identify Treg cells from LNs of these 
mice, instead of the intracellular marker Foxp3. The Treg population of Cflar
fl/fl
-
Foxp3
Cre/wt
 females was YFP, i.e. Cre negative, whereas about 9% of the Treg cells of 
Cflar
fl/wt
-Foxp3
Cre/wt
 females were YFP positive and almost 30 % of Cflar
wt/wt
-
Foxp3
Cre/wt
 females were YFP positive (Figure 24).  
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Figure 24. X chromosome random inactivation caused Treg chimeric females. 
Histogram graphs of YFP-Cre expression analyzed within the Treg compartment (CD4
+
 CD25
+
 
pre-gated) from LN cell suspension by flow cytometry. 
  
Cflar
Foxp3 
mice presented remarkable differences from the second week of life onwards 
compared to control mice, such as stunting, body weight reduction, crusting and 
scaliness in tails, ears and eyelids (Figure 25). 
 
 
 
 
 
 
 
 
Figure 25. Cflar
Foxp3 
mice showed macroscopic abnormalities and body weight reduction. 
(A) Picture of 24 days old Cflar
Foxp3
 mouse. (B) Comparative picture of 12 days old Cflar
Foxp3
 
mouse and littermate control in ventral decubitus position. (C) Scatter dot plot of body weight 
comparison between 2-3 weeks old Cflar
Foxp3 
mice and respective control littermates (n=8). 
Each point represents a single mouse. Horizontal lines represent the mean; error bars represent 
SEM. Statistical significances were calculated by two-tailed Mann-Whitney test. Bar graphs 
represent the mean; error bars represent SEM. Statistical analyses were performed by two-tailed 
Mann-Whitney tests; ***p<0.001. 
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The lymphoid organs of Cflar
Foxp3 
mice showed certain abnormalities. The thymus 
presented at least a 50% size reduction and peripheral lymph nodes were considerably 
enlarged compared to controls (Figure 26A). Furthermore, the size of the spleen was 
comparable, but considering the small dimensions and the reduced weight of Cflar
Foxp3 
mice compared to the controls these mice manifest a certain degree of splenomegaly 
(Figure 26B).  
 
 
 
 
 
 
 
Figure 26. Cflar
Foxp3 
mice showed morphological abnormalities in lymphoid organs. 
(A) Macroscopic appearance of lymphoid organs (thymus, spleen and lymph nodes) of 
Cflar
Foxp3
 mouse and littermate control. (B) Scatter dot plot of relative spleen weight of 2-3 
weeks old Cflar
Foxp3 
mice and respective control littermate. Each point represents the value of a 
single spleen (n=4). Horizontal lines represent the mean; error bars represent SEM. Statistical 
significances were calculated by two-tailed Mann-Whitney test. Bar graphs represent the mean; 
error bars represent SEM. Statistical analyses were performed by two-tailed Mann-Whitney 
tests; *p< 0.05. 
 
As Treg cells participate in the immune homeostasis by suppressing the Tcon cells, the 
CD4
+
 and CD8
+
 T cell subpopulations in these mice were examined by flow cytometry. 
Thymus of Cflar
Foxp3 
mice manifest a strong reduction of the CD4
+
 CD8
+
 double 
positive thymocytes resulting in the accumulation of the CD4
+
 and CD8
+
 single positive 
populations (Figure 27A, 27B and 27C). Likewise, the spleen of Cflar
Foxp3 
mice also 
showed higher frequencies of helper and cytotoxic T cells (Figure 27A, 24B and 27 C). 
Conversely, the frequencies of T cells were comparable in the peripheral lymph nodes 
of Cflar
Foxp3 
mice and control mice (Figure 27A, 27B and 27C). In contrast to the 
frequencies, the absolute numbers of CD4
+
 and CD8
+
 single positive cells were 
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significantly higher in the control mice, despite the frequencies were higher in the 
Cflar
Foxp3 
mice (Figure 27D and 27E). The strong reduction of the thymic size in 
Cflar
Foxp3 
mice explains the low absolute numbers of CD4
+
 and CD8
+
 single positive 
thymocytes in spite of showing higher frequencies than control mice. Regarding the 
periphery, CD4
+
 and CD8
+
 T cells showed higher frequencies in the spleen of 
Cflar
Foxp3 
mice, whereas the percentages of both cell types were very similar in the 
pLNs (Figure 27A, 27B and 27C). The absolute number of CD4
+
 and CD8
+
 T cell was 
higher in the spleen of Cflar
Foxp3 
mice, especially in the case of CD8
+
 T cells. In the 
case of pLN, the absolute cell numbers of both CD4
+
 and CD8
+
 T cells were slightly 
lower in Cflar
Foxp3 
mice compared to the controls (Figure 27D and 27E). 
 
 
 
Figure 27. CD4
+
 and CD8
+
 T cell cellularity was altered in Cflar
Foxp3
 mice. 
(A) Representative flow cytometric dot plots, (B and C) percentages and (D and E) absolute 
numbers of CD4
+
 and CD8
+ 
(both single positive) T cells respectively from thymus, spleen and 
peripheral lymph nodes of 2-3 weeks old Cflar
Foxp3 
mice and littermate control mice are shown 
(n=7 each; except thymus Cflar
Foxp3 
, n=4). Bar graphs represent the mean; error bars represent 
SEM. Statistical analyses were performed by two-tailed Mann-Whitney tests; *p< 0.05, 
**p<0.01, n.s., not significant. 
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Furthermore, the LNs of Cflar
Foxp3 
mice showed an unusual FACS forward/side scatter 
dot plot picture. The lymphocytes, analyzed by flow cytometry, presented reduced size 
and augmented cellular granularity. Moreover, the viability of the lymphocytes was 
considerably lower in Cflar
Foxp3
 mice compared to control mice. 
 
 
Figure 28. Reduced viability in lymphocytes of Cflar
Foxp3
 mice. 
(A) Representative FSC(Size)/SSC(Granularity) flow cytometric dot plots, (B) representative 
FSC(Size)/Live/Dead flow cytometric dot plots and (C) summary of viability from lymph nodes 
of Cflar
Foxp3 
mice and controls (n=7, each). 
 
Besides the remarkable variation in the T cell population of these mice, the condition of 
such cells was also altered in Cflar
Foxp3 
mice. Cell adhesion molecule CD62L and the 
CD44 molecule are typically used as markers to characterize the resting versus 
activation status of T cells. The CD62L homing receptor allows resting naïve T cells to 
enter into secondary lymphoid tissues. Alternatively, CD44 participates in the activation 
and recirculation of T cells, being a marker to identify effector-memory T cells. Both 
molecules are co-expressed in central memory T cells. The combination of CD62L and 
CD44 allows the discrimination between naïve, central-memory and effector-memory T 
cells. Flow cytometric analysis of CD4
+
 T helper and CD8
+
 T cytotoxic cells, using 
CD62L and CD44 markers, showed a clear shift from naïve T cells to effector-memory 
T cells in spleen and lymph nodes of Cflar
Foxp3 
mice, in contrast to control mice where 
most of them were naïve T cells (Figure 29). 
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Figure 29. CD4
+
 and CD8
+
 T cell populations were altered in Cflar
Foxp3
 mice. 
(A) Representative flow cytometric dot plots (B) and percentages of T cell activation markers 
CD62L and CD44 in CD4
+ 
T cells from spleen and peripheral lymph nodes of 2-3 weeks old 
Cflar
Foxp3 
mice and littermate control mice are shown. (C) Representative flow cytometric dot 
plots (D) and percentages of T cell activation markers CD62L and CD44 in CD8
+ 
T cells from 
spleen and peripheral lymph nodes of 2-3 weeks old Cflar
Foxp3 
mice and littermate control mice 
are shown. CD62L
+
/CD44
-
 cells are naïve T cells, CD62L
-
/CD44
+
 cells are effector-memory T 
cells and CD62L
+
/CD44
+
 cells are central memory T cells  (n=7 each). Bar graphs represent the 
mean; error bars represent SEM. Statistical analyses were performed by two-tailed Mann-
Whitney tests; *p<0.05, **p< 0.01, ***p<0.001. 
 
 
The changes in the Treg, CD4
+
 and CD8
+
 T cell compartments as well as the T cell 
activation was tracked during the first days of life of Cflar
Foxp3 
mice in order to 
describe the development of the scurfy-like phenotype produced in these animals. The 
Treg production in the thymus was constant and practically identical in Cflar
Foxp3
 and 
control mice during the analyzed period. The gradual decrease of regulatory T cells is 
clearly visible between days 6 and 8 of life of Cflar
Foxp3 
mice. From day 8 onwards, the 
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Treg cells were barely detectable in the spleen and lymph nodes of the deficient animals 
(Figure 30). 
 
Figure 30. Treg cells progressively disappeared during the first days of life in Cflar
Foxp3
 
mice. 
Frequencies of Treg cells in (A) thymus (B) spleen and (C) peripheral lymph nodes (LN) of 
Cflar
Foxp3 
and control
 
mice at day 6, 8 and 12 after birth. 
 
Following the disappearance of Treg cells at the day 8, the frequencies of the two 
subpopulations of T cells, CD4
+
 and CD8
+
, were substantially higher at day 12 of life in 
spleen of Cflar
Foxp3 
mice (Figure 31). Unlike the spleen, the frequencies of CD4
+
 and 
CD8
+ 
T cells did not show relevant changes in peripheral lymph nodes compared to 
control animals (Figure 31). 
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Figure 31. T cell frequencies increased in lymph nodes, but not in spleen, of Cflar
Foxp3
 
mice. 
Frequencies of CD4
+
 T cells in (A) thymus, (B) spleen and (C) peripheral lymph nodes (pLN) 
and CD8
+
 T cells in (D) thymus, (E) spleen and (F) peripheral lymph nodes (pLN) of Cflar
Foxp3 
and controls at day 6, 8 and 12 after birth. 
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Another consequence of missing Treg cells is the hyper-activation of the immune 
system. For this reason, the activation status of the T cell subpopulation was also 
tracked in the spleen and pLN of Cflar
Foxp3 
and control
 
mice within the first two weeks 
of life. In the case of Cflar
Foxp3 
mice, the naïve CD4
+
 T cells started to decrease 
vertiginously from day 6 of life in both organs and, consequently, the activated CD4
+
 
subpopulation rose (Figure 32).  On the other hand, regarding the CD8
+
 compartment, 
the naïve cells decreased and the activated cells increased in the spleen of Cflar
Foxp3 
mice at day 12. Looking at the peripheral lymph nodes of Cflar
Foxp3 
mice, the activated 
CD8
+
 T cells increased considerably, whereas the naïve CD8
+
 T cells of Cflar
Foxp3 
and 
control
 
mice behave in similar manner. 
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Figure 32. CD4
+
 and CD8
+
 became activated T cells in Cflar
Foxp3
 mice. 
Frequencies of naïve CD4
+
 T cells (CD62L
+
, CD44
-
) in (A) spleen and (B) peripheral lymph 
nodes (pLN) and activated CD4
+
 T cells (CD62L
-
, CD44
+
) in (C) spleen and (D) pLN of 
Cflar
Foxp3 
and control
 
mice at day 6, 8 and 12. Frequencies of naïve CD8
+
 T cells (CD62L
+
, 
CD44
-
) in (E) spleen and (F) pLN, and activated CD8
+
 T cells (CD62L
-
, CD44
+
) in (G) spleen 
and (H) pLN of Cflar
Foxp3 
and control
 
mice at day 6, 8 and 12.  
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A consequence of the T cell activation is the production of cytokines. Therefore, 
cytokine levels were measured in the serum of Cflar
Foxp3 
mice and control mice. Pro-
inflammatory cytokines such as IL-4, IL-5, IL-6, IFN, and TNF were extraordinarily 
higher in the serum of Cflar
Foxp3
mice (Figure 33). The elevated concentration of pro-
inflammatory cytokines may explain the degeneration and reduction of the thymus in 
Cflar
Foxp3
 mice. Additionally, the presence of autoantibodies was analyzed in the serum 
of Cflar
Foxp3 
mice and control mice. To this end, protein extracts from liver and kidney 
of RAG2-deficient mice were incubated with serum from both groups. The extracts 
incubated with Cflar
Foxp3
 mouse serum displayed presence of antibodies against liver 
and kidney in contrast to the controls which were negative for such antibodies (Figure 
33). 
 
 
 
 
 
 
 
 
Figure 33. Sera from Cflar
Foxp3
 mice contained large amounts of pro-inflammatory 
cytokines and autoantibodies. 
(A)Determination of the concentration of IL-4, IL-5, IL-6, IFN, IL-12p70, TNF in sera of 2 
weeks old Cflar
Foxp3
 mice and littermate control mice by Luminex assay (n=11 each). Bar 
graphs represent the mean; error bars represent SEM. Statistical analyses were performed by 
two-tailed Mann-Whitney tests; *p<0.05, ***p<0.001, n.s., not significant. (B) Autoantibody 
evaluation in sera from 2 weeks old Cflar
Foxp3
 mice and littermate control mice by incubation 
with protein extracts from kidney and liver of RAG-2-deficient mice. 
 
 
 
  
A B 
  
65 
 
Due to the hyper-activation of the immune system a leukocyte proliferation and tissue 
infiltration occurred in some organs of these mice. The following images show the 
structure alteration and massive infiltration occurred in liver, lung, pancreas and skin of 
Cflar
Foxp3 
mice in contrast to the controls, which exhibited normal tissue architecture 
(Figure 34).  
 
Figure 34. Massive leukocyte infiltration occurred in Cflar
Foxp3
 mouse tissues. 
Representative H&E staining of liver, lung, pancreas and skin sections from 2 weeks old 
Cflar
Foxp3
 mouse and littermate control are shown. 
 
 All these data together, indicate the development of a severe autoimmune disease in 
Cflar
Foxp3
 mice, resulting in a drastic reduction of the life duration of these mice, which 
die within the first three weeks of life (Figure 35). Most of the features and 
development of Cflar
Foxp3
 phenotype are comparable to scurfy phenotype. 
 
 
 
 
 
 
Figure 35. Cflar
Foxp3
 mice died prematurely within the first weeks of life. 
Kaplan Meier plot of the Cflar
Foxp3
 mice and littermate control mice (n=16 each group). 
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5.4 Treg cells are sensitive to CD95-, but not DR5- or TNFR1-induced cell death 
The Cflar
Foxp3
 animals demonstrated that cFLIP is essential to maintain Treg cell 
viability and therefore linking the extrinsic pathway of apoptosis to Treg cell 
homeostasis. However, the mechanism that explains how cFLIP protects Treg cells 
from cell death remained unclear. Since extrinsic apoptosis is initiated by death 
receptors stimulation, Treg cell death might be related specifically to one or various 
death receptors. In order to assess which death receptor/s produced cell death 
susceptibility in Treg cells, Tcon and Treg cells were purified from Foxp3-GFP reporter 
mice and cultured in the presence of CD95L, TRAIL, and TNF. After 16 hours in 
culture, the cell viability was analyzed by flow cytometry using AxV/7AAD staining. In 
parallel, untreated Tcon and Treg cells were cultured in the absence of death receptor 
stimulation. Cell viability was determined by the frequency of AxV
-
/7AAD
-
 treated 
cells relative to the respective AxV
-
/7AAD
-
 untreated samples. CD95L stimulation 
reduced considerably Treg cell viability, in agreement with previous reports
220
 whereas 
TRAIL and TNF did not manifest any impact on their viability (Figure 36). Moreover, 
Treg cells showed higher susceptibility to CD95L compared to Tcon cells, which 
showed a slightly reduction on its viability but not as pronounced as Treg cells (Figure 
36). 
 
 
Figure 36. CD95L enhances apoptosis in Treg cells. 
Statistical summary of Tcon and Treg cell viability relative to the respective untreated sample, 
assessed by flow cytometric analysis of AnnexinV/7AAD staining, is shown. The cell 
populations were purified from GFP-Foxp3 reporter mice by FACS sorting and cultivated 16 
hours in the presence of CD95L (20 ng/ml), TRAIL (20 ng/ml), TNF(20 ng/ml) and 
dexamethasone (DEX) (0.5 M) (n=4 each). Bar graphs represent the mean; error bars represent 
SEM. Statistical analyses were performed by two-tailed Mann-Whitney tests; *p<0.05; n.s., not 
significant. 
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To corroborate the impact of the CD95 system on Treg cell viability, sorted Tcon and 
Treg cells from Foxp3-GFP mice were stimulated with CD95L in the absence and 
presence of FasFc, which is a recombinant fusion protein of the immunoglobulin heavy-
chain constant region with the extracellular domain of the CD95 receptor, which is able 
to capture CD95L molecules. Untreated Tcon and Treg samples were used as reference 
to calculate the relative viability. Flow cytometric analysis based on AxV/7AAD 
determination revealed that the cells treated with FasFc showed a significant improved 
viability, indicating that FasFc competed with the added CD95L and reduced the input 
on CD95 receptor. Dexamethasone treatment induced efficiently massive cell death 
(Figure 37).  
 
 
Figure 37. CD95-mediated apoptosis is repressed by FasFc. 
Statistical summary of Tcon and Treg viability relative to the respective untreated samples, 
assessed by flow cytometric analysis of AnnexinV/7AAD staining, is shown. The cell 
populations were purified from Foxp3-GFP reporter mice by FACS sorting and cultivated 16 
hours in the presence of CD95L (20 ng/ml), CD95L (20 ng/ml) + FasFc (50 g/ml) and 
dexamethasone (DEX) (0.5 M) (n=4 each). Bar graphs represent the mean; error bars represent 
SEM. Statistical analyses were performed by two-tailed Mann-Whitney tests; *p<0.05; n.s., not 
significant. 
 
 
Alternatively, Tcon and Treg cells, sorted from lymph nodes of Foxp3-hCD2 reporter 
mice, were incubated in the absence or presence of CD95L. After 16 hours in culture, 
the cells were harvested, stained with the active caspase 3/7 fluorogenic substrate and 
analyzed by confocal microscopy. Like the flow cytometric results, Treg cells displayed 
higher caspase 3/7 activity indicating higher susceptibility to CD95L compared to Tcon 
cells (Figure 38).  
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Figure 38. Treg showed higher CD95-mediated apoptosis than Tcon cells 
(A) Representative confocal images and (B) summary viability graph. Active-caspase-3/7 
staining was performed in sorted Tcon and Treg cells purified from Foxp3-hCD2 reporter mice 
and cultured in the absence and presence of CD95L for 16 hours (n=4 each). Scale bars= 19 m. 
Bar graphs represent the mean; error bars represent SEM. Statistical analyses were performed 
by two-tailed Mann-Whitney tests; *p<0.05. 
 
 
5.5 Tcon and Treg cells show identical death receptor profile expression 
Extrinsic apoptosis is initiated by the stimulation of death receptors located on the cell 
surface
87
. In the previous results, Treg cells showed high susceptibility to cell death 
upon CD95L stimulation and this fact might be due to higher input generated by an 
augmented CD95 receptor expression. To evaluate the death receptor profile of Tcon 
and Treg cells, ex vivo cell suspensions from lymph nodes were stained with antibodies 
against the death receptors CD95, DR5 and TNFR1. Flow cytometric analysis 
comparing Tcon and Treg cell receptor expression showed similar profiles, with CD95 
receptor being strongly expressed in both cell types, whereas DR5 and TNFR1 
expression was very low in both cases (Figure 39). These results indicate that the 
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expression of CD95 receptor is not responsible for the higher CD95L susceptibility of 
Treg cells compared to Tcon cells. 
 
Figure 39. CD95 receptor is highly expressed in Tcon and Treg cells. 
Surface expression of the death receptors CD95, DR5, and TNFR1 on Tcon and Treg cells 
purified from Foxp3-hCD2 reporter mice determined by flow cytometry. Grey area represents 
the isotype antibody controls. 
 
5.6 Neither anti-CD95L nor QVD could protect the Treg cells of Cflar
Foxp3
 mice in 
vivo 
Because Treg cells highly expressed the CD95 receptor (Figure 39) and they displayed 
high sensitivity towards CD95L stimulation (Figures 36, 37 and 38), the CD95 system 
might mediate the cell death of cFLIP-deficient Treg cells in Cflar
Foxp3
 mice. Anti-
CD95L was injected into Cflar
Foxp3
 mice and control mice in order to block the CD95-
mediated pathway and to avoid the death signal in Treg cells. The mice were injected at 
day 7, 9 and 11 after birth and sacrificed at day 12. Two different anti-CD95L 
antibodies (Clones: MFL-3 and 3C82) were used in independent experiments. In both 
cases, the analyses showed comparable levels of Treg cells in the periphery of treated 
and untreated Cflar
Foxp3
 mice, whereas the Treg cell frequencies were remarkable 
higher in treated control animals (Figure 41). Thus, the CD95L antibody treatment did 
not have any effect on the animals. 
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Figure 41. Treg cells frequencies are remarkably lower after anti-CD95L treatment in 
Cflar
Foxp3
 mice. 
Flow cytometric dot plots, showing CD4
+
Foxp3
+
 frequencies, from thymus, spleen and lymph 
nodes (LN) of anti-CD95L (MFL-3)-treated  control, untreated Cflar
Foxp3
 and  anti-CD95L 
(MFL3) treated-Cflar
Foxp3
 mice. 
 
Since the absence of Treg cells in Cflar
Foxp3
 mice might be caused by apoptosis, these 
mice were treated with the pan-caspase inhibitor QVD in order to inhibit this cell death 
mechanism. Cflar
Foxp3
 mice and controls were treated with QVD at day 8, 9 and 10 
after birth and sacrificed at day 11. Again, the levels of Treg cells in the periphery, 
analyzed by flow cytometry were very low in Cflar
Foxp3
 mice whereas the controls 
displayed normal frequencies (Figure 42). The frequencies of Treg cells in the thymus 
were comparable in both cases (Figure 42). 
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Figure 42. Treg cells are barely detectable in the periphery of Cflar
Foxp3
 after QVD 
treatment. 
Flow cytometric dot plots, showing CD4
+
Foxp3
+
 frequencies, from thymus, spleen and lymph 
nodes (LN) of Cflar
Foxp3
 mice and controls after QVD treatment. Representative plots from 2 
independent experiments are shown. 
 
5.7 cFLIPL protects Treg cells from CD95-mediated cell death in vitro 
Considering that the CD95 receptor, i.e the input, was identical in Tcon and Treg cells 
but both cell types showed different susceptibility to CD95L stimulation, there had to be 
a differential mechanism that explains this different behavior. Since cFLIP is an 
important apoptotic inhibitor of the death receptor-mediated apoptosis
97
, it represented a 
potential regulator for the Treg susceptibility. To study the impact of cFLIP on CD95-
mediated apoptosis, Tcon and Treg cells from thymus of Cflar
Foxp3 
and control mice 
were cultured in the presence of CD95L, TRAIL and TNF. Tcon viability was slightly 
affected by CD95L, whereas TRAIL and TNF stimulation did not have any influence. 
Thymic Tcon cells from Cflar
Foxp3
 mice exhibited a slight reduction in viability 
compared to thymic Tcon cells from controls. Dexamethasone killed efficiently all cells 
(Figure 43A). These differences might be produced by an augmented sensitivity in Tcon 
cells from Cflar
Foxp3
 mice due to their enhanced activation status as a result of the 
cytokine storm produced in these mice. Importantly, notable differences were found 
between the viability of cFLIP-deficient and -proficient Treg cells upon CD95L 
stimulation (Figure 43B), indicating that cFLIP might increase the sensitivity threshold 
to CD95L-mediated cell death of Treg cells. 
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Figure 43. cFLIP-deficient Treg cells are less resistant than cFLIP-proficient Treg cells to 
CD95-mediated cell death. 
Statistical summary of Tcon (A) and Treg (B) viability assessed by flow cytometric analysis of 
AnnexinV/7AAD staining (control n=18, Cflar
Foxp3
 n=8). Cell populations were isolated from 
Cflar
Foxp3
 and control mice by FACS sorting and cultivated for 16 hours in the absence and 
presence of CD95L (5 ng/ml), TRAIL (20 ng/ml), TNF(20 ng/ml) and dexamethasone (DEX) 
(0.5 M). (Control n=18, CflarFoxp3 n=8). Bar graphs represent the mean; error bars represent 
SEM. Statistical analyses were performed by two-tailed Mann-Whitney tests; **p<0.01; n.s., 
not significant. 
 
 
 
So far, it was demonstrated that cFLIP protects Treg cells from CD95L-mediated 
apoptosis, but it was not clear why the proficient Treg cells manifested increased 
susceptibility to this particular cell death compared to Tcon cells. To clarify this point, 
the gene expression of the different cFLIP isoforms was examined in both cell types. 
mRNA levels of total cFLIP were comparable in Treg and Tcon cells, whereas the 
genetic expression of the long isoform cFLIPL was significant lower in Treg cells than 
in Tcon cells, in contrast to the short isoform cFLIPR (Figure 44). The low cFLIPL 
genetic expression explains the increased susceptibility to CD95L-mediated apoptosis in 
Treg cells. 
 
 
 
 
 
A B  
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Figure 44. Treg cells manifest lower cFLIPL genetic expression than Tcon cells. 
Expression of c-FLIP (A) and its isoforms c-FLIPL (B) and c-FLIPR (C) in Tcon and Treg cells 
purified from Foxp3-hCD2 reporter mice by FACS sorting and analyzed by qPCR (n= 17 each). 
Bar graphs represent the mean; error bars represent SEM. Statistical analyses were performed 
by two-tailed Mann-Whitney tests; *p<0.05; n.s., not significant. 
 
Even though both Tcon and Treg cell types get the same death input due to the identical 
death receptor expression, Treg cells manifested lower viability. This might be 
explained by the lower gene expression of cFLIPL, the long isoform of the apoptotic 
modulator, in Treg cells compared to Tcon cells. 
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6. Discussion 
6.1. Treg cells show an elevated apoptosis rate under steady-state conditions 
Treg cell function has been described as a mechanism to counterbalance the activity of 
the effector arm of the immune system. They have an essential role in the control of 
auto-reactive cells, particularly in blocking the activation of T cells that recognize self-
antigens, preventing the rise of autoimmune disorders.  Since their discovery by 
Sakaguchi in 1995
163
, Treg cells have been deeply investigated due to their relevance in 
immune homeostasis. Originally, early studies described Treg cells as an anergic 
subpopulation of CD4
+
 T cells expressing the alpha chain of the IL-2 receptor (CD25) 
that are able to prevent autoimmune activity caused by other cells of the immune 
system
196,197
. However, further investigations demonstrated that Treg cells manifest a 
relative high proliferation rate in steady-state conditions
198–201,221
. One of the most 
recent in vivo studies showed that 50 percent of the Treg cells proliferated after 10 days 
in homeostatic conditions using 5-bromo-2’-deoxyuridine (BrdU) labeling in mice199. 
They also demonstrated the high dynamics of these cells by depleting part of the Treg 
niche and tracking the rapid filling and the expression of Ki67 protein, which is 
typically upregulated during active phases of the cell cycle and absent in resting cells
199
. 
The high proliferation of the Treg cells might be related to their affinity to self-antigens. 
During development in the thymus, selected Treg cells have increased TCR affinity to 
self-antigens compared to positive selected conventional T cells
166–168
. This fact means 
that the Treg cells get continuous TCR stimulation, which would promote their 
proliferation. Due to the high proliferation of the Treg cells, a counterbalance 
mechanism is needed in order to maintain the population size and the immune 
homeostasis. Programmed cell death, and more specifically apoptosis, is proposed as 
the compensatory process that would dampen the elevated proliferation of Treg cells. 
Nonetheless, there are no studies showing clearly a high apoptosis rate in regulatory T 
cell so far. Recently, some studies described how the intrinsic pathway of apoptosis 
regulates Treg cell death. Initially, reduced expression of the pro-apoptotic protein BIM 
was reported in aged Treg cells, suggesting its role in the accumulation of these cells in 
aged mice
208
. Completing these findings, Tai and colleagues linked the expression of a 
pro-apoptotic protein signature, including BIM, with the function of the transcription 
factor Foxp3, which is essential for the Treg suppression capacity and, to date, the most 
reliable marker used to detect Treg cells. The pro-apoptotic role of Foxp3 is prevented 
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by common gamma chain-dependent cytokine signals during Treg development
198
. 
However, that study was focused mainly on the thymic development of Treg cells and it 
did not clarify how the Treg homeostasis is regulated after emigration from the thymus 
to the periphery. Few months later, Pierson and colleagues published a study, by which 
the role of the intrinsic pathway of apoptosis in Treg homeostasis was shown. In this 
study, the authors demonstrated that the cytokine IL-2 regulates the expression of the 
anti-apoptotic protein MCL-1, which is able to repress the BIM-dependent 
mitochondrial permeabilization and, in consequence, the initiation of the intrinsic 
pathway
199
 . Taken all together, these studies give a reasonable explanation of the 
mechanism that regulates the Treg population size and the immune homeostasis, giving 
a prominent role to the intrinsic pathway of apoptosis regulated by the cytokine IL-2. 
Nevertheless, none of them showed a proof that peripheral Treg cells undergo cell death 
in order to balance their elevated proliferation under steady-state conditions and they 
assumed that the Treg cells manifest a raised apoptosis rate.  
Consistent with these assumptions, evidences of the elevated apoptosis rate in Treg cells 
compared to Tcon cells are demonstrated in this thesis by means of ex vivo analysis. In 
all the lymphoid organs analyzed, Treg cells had a higher cell death rate than Tcon cells 
using different techniques to detect apoptosis, including mitochondrial membrane 
depolarization (Figure 13), phosphatidylserine exposure on the outer leaflet of the 
plasma membrane (Figure 14) and activation of effector caspases (Figure 15). These 
data would support the idea that Treg cells are a very dynamic population during 
homeostatic conditions, which proliferate continuously, presumably due to constant 
TCR stimulation. The elevated proliferation rate needs a counterbalance mechanism in 
order to keep the homeostasis. Since apoptosis is a tight regulated process, it represents 
a suitable mechanism to equilibrate the size of the Treg cell population
87
. The pan-
caspase inhibitor QVD was able to improve the viability of the Treg cells in vitro, 
corroborating the role of apoptosis in Treg cell death (Figure 16). Supporting this idea, 
IL-2 stimulation, which can inhibit apoptosis in Treg cells
198
, increased their viability of 
the cultures.  
T cell activation, triggered by the TCR, can promote either cell proliferation or 
apoptosis. CD28 co-stimulation increases the expression of the anti-apoptotic protein 
BCL-XL
216
, whereas in the absence of CD28-induced signal transduction, TCR 
stimulation promotes apoptosis through the BH3-only protein BIM
143,222
. Moreover, 
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TCR stimulation can also trigger, through the CD95 system, activation-induced cell 
death in T cells
223–225
. In the case of Treg cells, the induction of cell death via TCR 
stimulation was partially abolished by QVD as well as IL-2 (Figure 17), demonstrating 
the contribution of apoptosis in Treg cell death. 
 
6.2. Treg cells behave like TCR-activated Tcon cells 
Based on the previous experiment, neither QVD nor IL-2 did show any effect on the 
viability of unstimulated T con cells. Since naïve Tcon cells do not express the high 
affinity IL-2 receptor, their unresponsiveness upon IL-2 stimulation was expected. 
However, the insignificant influence of QVD on Tcell viability manifests that Tcon cell 
death was minimally mediated by apoptosis in the cell cultures (Figure 18). 
Interestingly, anti-CD3-stimulated Tcon cells behaved similar to Treg cells to QVD 
treatment. In this case, the viability of the Tcon cells improved by QVD treatment, 
indicating that the TCR-mediated cell death was occurring by apoptosis. Taken 
together, these results demonstrate that apoptosis takes place in Treg cells and activated 
Tcon cells, but not in resting Tcon cells. Remarkably, only IL-2 was not sufficient to 
improve the viability of anti-CD3-stimulated Tcon cells (Figure 19), while this cytokine 
improved the viability of Treg cells in the absence and presence of anti-CD3 (Figures 
16 and 17). Thus, in terms of apoptosis activity, Treg cells are comparable to TCR-
stimulated Tcon cells. In fact, TCRs from Treg cells have a higher affinity to self-
antigens compared to Tcon cells
160
 and therefore, the Treg cells are constantly exposed 
to TCR stimulation in the organism. Combined stimulation with TCR, CD28 and IL-2 
promotes the proliferation and represses the apoptosis in Tcon cells
216
. This fact 
correlates with the results from the Tcon and Treg cell cultures stimulated in parallel 
with PMA, ionomycin and IL-2, which did not show active caspase 3 (Figure 20). 
Conversely, unstimulated Treg cells showed active caspase 3, in contrast to 
unstimulated Tcon cells (Figure 20). In addition, Treg cells display markers which are 
expressed in Tcon cells only upon activation, such as CD25, GITR, CD154, CTLA-4 
and OX40
226
. These results support the idea that Treg cells behave like TCR-stimulated 
T cells, which undergo apoptosis unless they get CD28 and IL-2 stimulation. 
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6.3. X chromosome inactivation produces Treg chimeras in females 
Despite several studies related to the regulation of Treg cell death with the intrinsic 
pathway of apoptosis, the contribution of the extrinsic pathway was neglected. The 
regulation of the Treg cell apoptosis by the extrinsic pathway, through the TRAIL 
system, was negated in a report where the authors showed that the Treg cells were 
resistant to TRAIL-mediated apoptosis
227
. Peculiarly, Treg cells proliferated in contact 
to bone marrow derived-dendritic cells expressing TRAIL, whereas Tcon cells 
underwent apoptosis upon the same stimulation. Although both cells types expressed 
the TRAIL receptor DR5, the presence of the decoy receptor mDc-TRAILR1 in Treg 
cells would protect the Treg cells but not the Tcon cells from the death input signaling. 
 In order to assess the role of the extrinsic pathway of apoptosis in Treg cell 
homeostasis, the death receptor inhibitor cFLIP was deleted in Treg cells in mice, using 
the Cre-loxP recombination system. In this case, the expression of recombinase Cre was 
under the control of Foxp3 promotor and Cflar, the gene encoding cFLIP, was flanked 
by loxP sites floxed. This results in the Cre-mediated deletion of Cflar when Foxp3 is 
expressed. Heterozygous animals for both alleles, and hemizygous males in the case of 
Foxp3
Cre/Y
, were crossed in order to achieve the deletion of Cflar in Treg cells. Multiple 
combinations of genotypes were generated, including Cflar
Foxp3
 mice, which developed 
numerous abnormalities compared to the rest of the resulting genotypes (Figure 21). 
Remarkably, Cflar
fl/fl 
- Foxp3
Cre/wt
 females, despite containing both Cflar alleles floxed 
and one Cre-expressing chromosome, did not show any abnormality and were included 
in the group of control mice. This phenomenon is due to the fact that Cre expression is 
under the control of the Foxp3 promoter, which is located in the X chromosome. In 
females, one X chromosome is randomly inactivated during the embryogenesis
228
. As a 
consequence, a part of the Treg-precursor cells in the bone marrow had the Cre-
containing X chromosome inactivated and another part of Treg-precursor cells had the 
Cre-containing X chromosome activated. Silencing of one of the X chromosomes 
produced a chimeric mouse, which results in the generation of two different 
populations, Cre-expressing Treg cells and Cre-deficient Treg cells, within the same 
animal. In these mice, Cre-proficient Treg cells die, Cre-deficient Treg cells develop 
normally and fill the niche by, presumably, homeostatic proliferation, being comparable 
to Cflar
fl/fl 
- Foxp3
wt/wt
 genotype. Moreover, the YFP, i.e. Cre, expression within the 
Treg compartment of Cflar
fl/fl 
- Foxp3
Cre/wt
 females was undetectable (Figure 24), 
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corroborating the idea that only Cre-deficient Foxp3 positive cells remain in the Treg 
population. This would explain that although both Cflar alleles were floxed, they 
persisted in the genome due to the Cre deficiency. 
Furthermore, theoretically, the Treg compartment of Cflar
wt/wt
-Foxp3
Cre/wt
 females, due 
to the random X chromosome inactivation, would be equally distributed between Cre-
expressing, i.e. YFP positive cells, and non-expressing, i.e. YFP negative cells. In these 
mice, Treg cells are fully cFLIP-proficient and both cell types should respond 
identically to cell death. However, the analysis revealed that the percentage of Cre-
expressing Treg was lower than the expected 50%. This might be due to a 
contamination of activated Tcon cells, which express CD25 and were gated in the 
identification of the Treg compartment or might be due to a possible YFP instability 
affecting its detection by the cytometer. Alternatively, Cflar
fl/wt
-Foxp3
Cre/wt
 females had 
about 9% of YFP-expressing Treg cells, indicating a gene-doses effect between the 30% 
of YFP-expressing Treg cells in Cflar
wt/wt
-Foxp3
Cre/wt
 females and the totally loss of 
YFP-expressing Treg cells in Cflar
fl/fl
-Foxp3
Cre/wt
 females (Figure 24). 
Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome is an 
autoimmune disease caused by the dysfunction of Foxp3, which is an essential 
transcription factor for Treg function
170
. Remarkably, all the cases of IPEX syndrome 
have been reported on males, being carrier females completely healthy
229
. X 
chromosome inactivation and the proliferation capacity of Treg cells to refill the niche 
would explain why carrier females do not develop any symptom. Like in the Foxp3
Cre/wt
 
mice, Treg compartment would consist in 2 different subpopulations since the Foxp3 
gene is located at the X chromosome. Due to random X chromosome silencing, one 
population would express the WT allele and the other population would express the 
mutated/inactive allele. As a consequence, the Foxp3-mutated Treg cells would not 
develop and all the Treg cells in the organism would express the WT allele. This 
situation is comparable to the absence of YPF positive Treg cells in Cflar
fl/fl
-Foxp3
Cre/wt
 
female mice. Considering this, females are Treg chimeras, having one portion of the 
Treg population expressing the paternal allele and the other portion the maternal allele, 
even when both Foxp3 alleles are functional. 
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6.4. Lack of cFLIP in murine Treg cells results in the disappearance of the Treg 
cells in the periphery but not in the thymus 
The deletion of Cflar in Treg cells of Cflar
Foxp3
 mice had a notable impact in the Treg 
cell population. Treg cells were barely detectable in the periphery of these mice (Figures 
22 and 23). Paradoxically, Treg cells were produced continuously in the thymus 
(Figures 22 and 23) in spite of the serious alterations suffered in this organ, such as 
reduction of size and loss of double positive thymocytes (Figures 23 and 26). The 
integrity of Treg cell development was not affected because the deletion of Cflar 
occurred in the last developmental step, when Foxp3 is expressed. On the other hand, it 
was not demonstrated that the deletion of Cflar caused directly the death of the cell. 
This deletion might cause an increase of cell death sensitivity mediated by further 
stimuli. Another possibility is that cFLIP is intrinsically necessary for Treg survival, 
and its lack is sufficient to cause cell death. If this is the case, the presence of Treg cells 
in the thymus might be due to a delay in the deletion of Cflar by Cre or/and due to a 
remaining cFLIP protein previously expressed in the cell. Alternatively, the presence of 
Treg cells in the thymus, but not in the periphery, might be due to the fact that the death 
ligand encounter occurs in the periphery, but not in the thymus. Taken together, these 
findings might explain why the Treg cells are barely detectable in the periphery of 
Cflar
Foxp3
 mice, which are able to produce thymic Treg cells but incapable to maintain 
them in the periphery. The lack of Treg cells in peripheral organs of Cflar
Foxp3
 mice 
triggers a systemic autoimmune disease due to the absence of a control capable to 
counterbalance auto-reactive cells.  
 
6.5. Absence of Treg cells in Cflar
Foxp3
 mice originates an autoimmune disorder 
comparable to scurfy phenotype 
Cflar
Foxp3
 mice developed similar symptomatology to scurfy phenotype
174
, 
characterized by a fatal autoimmune disease producing stunting, scaly and ruffled skin, 
reddened eyes, splenomegaly, lymph nodes enlargement, and death within the first 
weeks of life (Figures 25 and 26). The absence of suppressive cells produced hyper-
activation of the immune system because of the rise of auto-reactive cells and the 
massive cytokine production. The development of fatal autoimmunity is another proof 
  
80 
 
of the importance of the Treg cells in immune homeostasis, despite the fact that they 
represent only about 5-10 % of the CD4
+
 T cell compartment.  
Together with the rise of inflammatory cytokines (Figure 33), which has also been 
reported in scurfy mice
230,231
 , the CD4
+
 and CD8
+
 T cells were highly activated in 
spleen and lymph nodes of Cflar
Foxp3
 mice (Figure 29). In all cases, the T cells of 
Cflar
Foxp3
 mice shifted from a naïve to an activated status. In the pLN of control mice, 
the naïve CD8
+
 T cell population also decreased (Figure 32) but they did not shift to an 
activated status (Figure 32). Instead, they became central-memory T cells (CD62L
+
, 
CD44
+
) in the lymph nodes. This effect did not occur in the CD4
+
 T cells of control 
mice because the central-memory T cells are more prominent in CD8
+
 T cells. The 
hyper-activation of the immune system in Cflar
Foxp3
 mice produced the accumulation 
of CD4
+
 and CD8
+
 T cells in the spleen (Figure 27).  The frequencies of these cells were 
comparable in pLN of Cflar
Foxp3
 mice and control mice. However, the absolute cell 
number was slightly lower in Cflar
Foxp3
 mice (Figure 27), although the lymph nodes 
were substantially larger than in the control mice (Figure 26). Moreover, the small size 
and augmented granularity of a considerable group of lymphocytes of Cflar
Foxp3
 mice, 
together with a remarkable low viability (Figure 28) indicated that lymphocytes of 
Cflar
Foxp3
 mice died and accumulated massively in the lymph nodes. This would 
explain why the frequencies of T cells, which were calculated excluding the death cells, 
were similar in Cflar
Foxp3
 mice and controls whereas the absolute T cell number was 
lower in the enlarged lymph nodes of Cflar
Foxp3
 mice (Figure 27). 
 
6.6. Blocking CD95L or pan-caspase inhibitor treatment is not sufficient to rescue 
the scurfy-like phenotype on Cflar
Foxp3
 
Rescue or decreasing symptoms of the autoimmunity in scurfy mice by T cell transfer or 
bone marrow transplant has been reported
232
. cFLIP deficiency in Treg cells caused an 
outcome that was similar to the one in scurfy mice (Figures 23, 25 and 26). Since cFLIP 
is an inhibitor of the death receptor-mediated pathway
97
 and the expression of CD95 in 
Treg cells was higher compared to other death receprors (Figure 39), the vulnerability of 
the Treg cells in Cflar
Foxp3
 mice might be explained by a lack of protection triggered by 
the CD95 system. Thereby, anti-CD95L was injected into the Cflar
Foxp3
 mice in order 
  
81 
 
to inhibit the CD95 input in the Treg cells. These experiments were performed using 
independently two monoclonal anti-CD95L antibodies obtained from different clones. 
Nevertheless, both anti-CD95L antibodies did not have any impact on the development 
of the autoimmunity on Cflar
Foxp3
 mice (Figure 41). This might suggest that the 
absence of Treg cells in the periphery of Cflar
Foxp3
 mice is not related to increased 
CD95-mediated apoptosis. Besides the role of cFLIP as anti-apoptotic inhibitor, cFLIP 
activity has been related to the activation of the NF-B and ERK pathways126,233. 
Moreover, Zhang and colleagues showed that cFLIP is essential for T lymphocyte 
proliferation in a NF-B-independent manner233. Therefore, the disappearance of Treg 
cells in the periphery of Cflar
Foxp3
 mice might be produced by a proliferation defect in 
the Treg cells. Supporting this idea, pan-caspase inhibitor treatment did not ameliorate 
the reduction of Treg cells in Cflar
Foxp3
 mice, suggesting indirectly that cFLIP is 
involved in the proliferation of the Treg cells (Figure 42). However, the apoptosis of 
Treg cells in Cflar
Foxp3
 mice cannot be totally excluded by the anti-CD95L and QVD in 
vivo treatments. On the one hand, necroptosis might get activated as a back-up cell 
death mechanism when apoptosis is inhibited by QVD. On the other hand, the effect of 
the two treatments might be masked by the high dynamics of the Treg cells. This would 
produce a very limited rescue effect over the time due to insufficient anti-CD95L or 
QVD availability. Alternatively, flanking the CD95 gene sequence by loxP sites, i.e. 
deleting CD95 genetically, would help to determine whether the absence of Treg cells in 
Cflar
Foxp3
 mice is mediated by the CD95 system. 
 
6.7. cFLIP-deficient Treg cells manifest higher susceptibility to CD95L in vitro 
stimulation 
In contrast to the results from the anti-CD95 in vivo treatment (Figure 41), suggesting 
that CD95L is not involved in Treg apoptosis, in vitro experiments showed that cFLIP 
confers resistance to CD95-mediated apoptosis. Treg cells from Cflar
Foxp3
 mice were 
more susceptible to cell death than Treg cells from control mice upon CD95L 
stimulation in vitro (Figure 43). That indicates that cFLIP has anti-apoptotic function in 
Treg cells. Indeed, this thesis corroborates previous findings
220
 , showing that Treg cells 
were highly sensitive to CD95-induced apoptosis compared to Tcon cells (Figures 36, 
37 and 38). Despite Treg and Tcon cells manifesting comparable CD95 receptor 
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expression (Figure 39), the reduced expression of cFLIPL in Treg cells (Figure 44) 
might explain the differences in terms of resistance to CD95-mediated apoptosis. 
 
6.8. Concluding remarks 
Immune homeostasis needs to be tightly regulated for maintaining the capacities of the 
immune system to protect the organism against multiple threats as well as for being able 
to tolerate their own structures. Due to their suppressive capacity, Treg cells are a vital 
cellular mechanism to block autoreactive cells, and avoid autoimmune development. 
Therefore, the behavior of the Treg population is crucial to keep immune homeostasis. 
This thesis demonstrated that Treg cells are a dynamic population with an elevated 
apoptosis rate compared to conventional T cells. Furthermore, the findings approach 
Treg cells to the status of activated cells. 
Moreover, the role of cFLIP in Treg cells was investigated in order to better understand 
the behavior of Treg cell homeostasis and progress in the knowledge of their regulation. 
The deficiency of cFLIP resulted in a scurfy-like phenotype in mice, demonstrating the 
vital role of these proteins in Treg cells. The autoimmunity developed in these mice is 
presumably produced by the absence of Treg cells. The lack of Treg cells in the 
periphery of Cflar
Foxp3
 mice might be due to proliferation defect or enhanced apoptosis. 
The low gene expression of cFLIPL compared to Tcon cells might explain the enhanced 
vulnerability of Treg cells to CD95 in vitro stimulation. However, the exact cause for 
the Treg absence in Cflar
Foxp3
 mice remains still not completely resolved and needs 
further investigations. 
Due to their suppressive activity, the modulation of the Treg population might be 
beneficial in pathogenic conditions. For instance, reducing the Treg compartment in a 
tumor environment might enhance the immune response against the cancer cells. 
Alternatively, boosting the Treg population might increase the tolerance to self-antigens 
in autoimmune diseases. Hence, cFLIP represents a potential target to modulate Treg 
homeostasis in order to regulate the immune response against cancer and autoimmune 
diseases. 
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7. Abbreviations  
7AAD 7-aminoactinomycin D 
A1A BCL-2-related protein A1A 
AICD Activation-induced cell death  
AIRE Autoimmune regulator  
Ala Alanine 
APAF-1 Apoptotic protease activating factor 1  
Asp Aspartic acid 
ATP Adenosine triphosphate  
AxV Annexin V 
BAD BCL-2 antagonist of cell death  
BAK BCL-2-antagonist/killer-1 
BAX BCL-2-associated X protein 
BCA Bicinchoninic acid  
BCL B-cell lymphoma 
BCL-2 B-cell lymphoma-2 
BCL-W B-cell lymphoma-2-like-2 
BCL-XL B-cell lymphoma-extra-large protein 
BH BCL-2 homology 
BID BH3-interacting domain death agonist 
BIK BCL-2-interacting killer  
BIM BCL-2-like-11 
BMF Bcl-2-modifying factor  
BOK BCL-2-antagonist/killer-1 
BrdU 5-bromo-2’-deoxyuridine 
cAMP Cyclic adenosine monophosphate 
CARD Caspase recruitment domain  
CD Cluster of differentiation 
CD95L CD95 ligand 
cFLIP Cellular FLIP 
cFLIPL Cellular FLIP long 
cFLIPR Cellular FLIP Raji 
cFLIPS Cellular FLIP short 
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CTL Cytotoxic T lymphocytes  
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
Cys Cysteine 
DAMP Damage-associated molecular patterns 
DC Dendritic cell 
DD Death domain  
DED Death effector domain  
DEX Dexamethasone 
DIABLO Direct IAP binding protein with low pI 
DISC Death-inducing signaling complex 
DNA  Deoxyribonucleic acid 
DP Double positive 
DR Death receptor 
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasmic reticulum 
FACS Fluorescence-activated cell sorting 
FADD Fas-Associated Death Domain  
FLICE FADD-like IL-1-converting enzyme 
FLIP FLICE-inhibitory protein 
Foxp3 Forkhead box protein 3 
FPLC Fast protein liquid chromatography  
GFP Green fluorescent protein  
GITR Glucocorticoid-induced TNFR family related gene 
Gln Glutamine 
Gly Glycine 
GTP Guanosine triphosphate  
H&E  Hematoxilin and eosin 
hCD2 Human CD2 
His Histidine 
HRK Harakiri  
IAP Inhibitor of apoptosis proteins  
IDO Indoleamine 2,3-dioxygenase  
IFN Interferon gamma 
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Ig Immunoglobulin  
IKK Inhibitor of B kinase 
IL-2 Interleukin 2 
IL-4 Interleukin 4 
IL-5 Interleukin 5 
IL-6 Interleukin 6 
IL-10 Interleukin 10 
IL-12 Interleukin 12 
IL-35 Interleukin 35 
IPEX Idiopathic polyendocrinopathy X-linked 
LN Lymp nodes 
MCL-1 Myeloid cell leukaemia 1 
MHC Major histocompatibility complex  
mLN Mesenteric lymph nodes 
MMP Mitochondrial membrane potential  
mTOR Mammalian target of rapamycin 
Mut Mutant 
NF-B Nuclear factor B 
NK Natural Killer  
OMM Outer mitochondrial membrane  
PAMP Pathogen associated molecular patterns  
PBS Phosphate buffered saline 
PCR Polymerase chain reaction  
PI3K-I Phosphatidylinositol 3-kinase-I 
pLN Peripheral lymph nodes 
PMA Phorbol 12-myristate 13-acetate  
PS Phosphatidylserine  
PUMA BCL-2 binding component-3 
PVDF Polyvinylidene difluoride  
qRT-PCR Quantitative real-time polymerase chain reaction  
QVD Q-VD-OPh  
RAG2 Recombination activating gene 2 
RIP-1  Receptor-interacting protein 1 
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ROS Reactive oxygen species  
RT Room temperature 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEM Standard error of mean 
SMAC Second mitochondria-derived activator of caspases 
SNP Single nucleotide polymorphism 
tBID Truncated BID 
TBS Tris-buffered saline  
Tcon Conventional T 
TCR T cell receptor  
TEC Thymic epithelial cells  
TGF- Transforming growth factor beta  
Th T helper  
TMRE Tetramethylrhodamine ethyl ester  
TNF Tumor-necrosis factor  
TNFR1 TNF receptor 1 
TRADD TNFR1-associated death domain protein 
TRAF TNFR-associated factor 
TRAIL TNF-related apoptosis-inducing ligand 
TRAILR TNF-related apoptosis-inducing ligand receptor  
Treg  Regulatory T  
UBC Ubiquitin-conjugating enzyme E2D 2A 
WT Wild type 
XIAP X-linked inhibitor of apoptosis protein 
YFP Yellow fluorescent protein  
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